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ABSTRACT
To investigate the potential of chemotherapeutants to control the oyster pathogen 
Perkinsus marinus, anticoccidial and antifungal compounds were tested in vitro on infected 
hemolymph and cultured P. marinus cells and in vivo on infected oysters. In addition, 
acute toxicity to oysters was determined for six anticoccidials.
In vitro experiments with infected hemolymph consisted of 24 h exposure of 0.2 
mL hemolymph aliquots to concentrations ranging from 100 mg/L to 0.01 mg/L of 
amphotericin-B, amprolium, arprinocid, cycloheximide, lasalocid, malachite green, 
monensin, sulfadimethoxine, and a potentiated sulfadimethoxine, followed by incubation in 
fluid thioglycollate medium (FTM) to determine prezoosporangia abundance. Lasalocid, 
malachite green, and amphotericin-B were the most effective compounds reducing 
prezoosporangia abundance, relative to the untreated control group, at concentrations as 
low as 10 mg/L. Cycloheximide, monensin, and to a lesser extent sulfadimethoxine, were 
also effective but only at the highest concentration tested (100 mg/L). At concentrations 
lower than 10 mg/L, none of the compounds tested had a significant effect on abundance of 
prezoosporangia.
In vitro experiments with cultured P. marinus consisted of 24 h exposure of 10^ 
cells to 100 mg/L, 10 mg/L, and 1 mg/L of amphotericin-B, and 100 mg/L of cimetidine, 
cycloheximide, fumagillin, 5-fluorocytosine, ketoconazole, lasalocid, and monensin, 
followed either by incubation in FTM to determine abundance and size of prezoosporangia, 
or by addition of Neutral Red to determine cell viability. Amphotericin-B, lasalocid, and 
monensin were effective in reducing prezoosporangia abundance, size, and/or cell viability. 
No effects of cycloheximide on cultured cells were apparent
Lasalocid, monensin, and malachite green, were toxic to oysters at concentrations 
below 10 mg/L. The 96-hr. LC50 for lasalocid was 0.59 mg/L. No median lethal dose was 
determined for monensin or malachite green, but oyster mortality resulted from exposures 
ranging from 1 mg/L to 10 mg/L of either compound.
In three in vivo experiments, infected oysters were exposed to amprolium, 
arprinocid, cycloheximide, lasalocid, monensin, malachite green, potentiated 
sulfadimethoxine, and sulfadimethoxine at various concentrations. Only cycloheximide was 
effective in reducing P. marinus infections. After 15 days of exposure to 10 mg/L of 
cycloheximide, weighted prevalence significantly declined from 3.78 in untreated controls 
to 2.10 in treated oysters. In addition, infections as measured by repeated hemolymph 
samples from individual oysters, significantly decreased after treatment Extension of
cycloheximide exposure to 30 days similarly reduced P. marinus prevalence and weighted 
prevalence. Infections, however, were not completely eliminated even after 30 days of 
exposure to 10 mg/L of cycloheximide. Furthermore, infections progressed after treatment 
was discontinued as indicated by an increase in weighted prevalence from 0.71 at the end 
of treatment to 1.31 one month later.
In summary, cycloheximide baths of at least 10 mg/L renewed every other day for 2 
weeks were necessary to reduce P. marinus infections in oysters held at 20 °C and 20 ppt 
Continuation of the treatment schedule for 2 additional weeks did not result in eradication 
of parasites, and infections relapsed once treatment stopped.
IN VITRO AND IN VIVO EFFECTS OF CHEMOTHERAPEUTANTS ON THE 
OYSTER PARASITE, PERKINSUS MARINUS
INTRODUCTION
The oyster industry in Virginia experienced serious decline since an MSX epizootic 
caused large scale mortality to oysters in the lower portion of the Chesapeake Bay in 1960 
(Burreson 1991a, Haskin & Andrews 1988, Hargis & Haven 1988). Between 1960 and 
1985 Haplosporidium nelsoni, the causative agent of MSX disease, was responsible for 
most of the disease induced mortality in Chesapeake Bay oysters. Since 1985, however, 
Perkinsus marinus has gradually replaced H. nelsoni as the most important pathogen in 
Chesapeake Bay. Estimates of up to 50% total annual oyster mortality have been attributed 
to P. marinus disease (Andrews, 1988a). Although over harvesting and water quality 
deterioration have contributed to the decline of the oyster resource and industry (Hargis & 
Haven 1988), disease mortality and decreased investment in private farming, because of the 
fear of losses to disease, are believed to be primarily responsible for much of the decline in 
oyster landings (Burreson, 1991a).
Sublethal effects of P. marinus on oyster growth and reproduction have also been 
proposed as additional factors impacting production. Ray et al. (1953) reported an average 
of 33% reduction in condition index of heavily infected oysters compared to uninfected 
oysters. Andrews (1961), and Menzel and Hopkins (1955) found that P. marinus infection 
reduces oyster shell growth. Similarly, Paynter and Burreson (1991) correlated shell 
growth reduction and oyster condition reduction with the acquisition and progression of P. 
marinus infections. Mackin (1962) reported that infections disrupted gonadal tissue and 
impaired gonad development Decrease in oyster setting as a result of lethal and sublethal 
effects of disease on broodstock has been proposed as an additional factor contributing to 
the decline of oyster populations (Haven & Fritz 1985, Ford & Figueras 1988).
Perkinsus marinus is endemic in most of the lower Chesapeake Bay including the 
lower sections of all rivers in Virginia. The parasite also now occurs in the upper parts of
the rivers, but abundance is low and little disease mortality occurs there. Perkinsus 
marinus has thrived in densely planted private beds, but it has persisted even in sparsely 
populated public beds. It is not clear how oyster density affects disease transmission, but 
denser beds seem to have had the highest mortality (Andrews 1988a). Infections follow a 
seasonal pattern of maximum prevalence and intensity during summer and fall and 
minimum prevalence and intensity during winter and spring. Temperature and salinity 
modulate the seasonal pattern of infections and play a major role in determining the 
distribution and abundance of the parasite. At temperatures above 20 °C and salinities 
above 12 ppt P. marinus develops rapidly and can be lethal to oysters within a month. In 
natural beds most oysters die after two consecutive summers of exposure (Andrews, 
1988a). In response to above normal seasonal temperature and salinity regimes such as the 
persistent droughts in 1985-1988, P. marinus increased its distribution and abundance 
(Burreson and Andrews 1988). Below normal seasonal salinities, such as the ones 
registered in 1989 and 1990 due to abnormally high rainfall, however, did not eradicate the 
pathogen (Burreson 1991b). Therefore, for P. marinus disease to disappear, below 
average temperature and salinity conditions may need to persist for a very long time.
The taxonomy of this parasite is still controversial. Initially, P. marinus was placed 
in the fungal genus Dermocystidium on the basis of the characteristic eccentric nucleus and 
vacuole with refringent vacuoplast observed in hematoxylin and eosin stained sections of 
infected oyster tissue (Mackin et al. 1950). Later, it was transferred to the fungal genus 
Labyrinthomyxa by Mackin and Ray (1966). More recently, electron microscopic 
observations of the apical complex of zoospores by Perkins (1976a) led Levine (1978) to 
create the class Perkinsea and the genus Perkinsus within the protozoan phylum 
Apicomplexa to accommodate P. marinus. Although this latter classification has been 
endorsed by the Society of Protozoologists (Levine 1980), the taxonomic status of P. 
marinus and indeed of the phylum Apicomplexa, has not been settled. Since 1980, there 
have been 3 independent revisions of the phylum Apicomplexa, reviewed by Canning
(1986), which propose to re-establish Sporozoa as the phylum name. Two revisions, by 
Krylov & Kostenko (1981) and Corliss (1984), propose to include P. marinus within the 
sporozoans under a new class or order. The third proposal, by Vivier (1982), disregards 
the similarities of the apical complex in P. marinus with that of other sporozoans, and 
suggests placing the species within the flagellates based on the lack of a sexual phase in its 
life cycle. Recent biochemical studies of Perkinsus sp. indicate that the genus is 
phylogenetically closer to dinoflagellates and to coccidian and piroplasm apicomplexans 
than to fungi or flagellates (Goggin & Barker 1993).
In oysters, P. marinus can be detected by direct microscopic examination of tissue 
or hemolymph smears (Mackin, 1962). Those methods, however, are not suitable for 
routine diagnosis given the difficulty in observing a parasite of such a small size. The 
smallest meronts found in oyster tissue are 2-4 |im in diameter (Perkins, 1988). 
Histological sectioning and staining with hematoxylin and eosin can also be used for 
diagnosis but these are time consuming methods (Johnson and Sparrow, 1961). A rapid 
diagnostic method currently used is the thioglycollate culture method developed by Ray 
(1952). Ray's method consists of incubating whole animal tissues or pieces of infected 
oyster tissues in fluid thioglycollate medium (FTM). This procedure results in enlargement 
of P. marinus meronts (called prezoosporangia or hypnospores after enlargement) to sizes 
that are easily observed by light microscopy, especially after staining with iodine. The 
oyster tissues that are usually examined ate mantle, gill, and rectum. Extensive use of the 
thioglycollate culture method by oyster biologists since the 1950s has shown that P. 
marinus is an important agent of oyster mortality along the east and gulf coasts of the 
United States (Ray 1954, Mackin 1962, Andrews 1976). For assessment of P. marinus 
infection intensity, Ray (1954) and later Mackin (1962), developed ordinal scales which 
rate the relative abundance and distribution of the parasite in pieces of oyster tissue. More 
quantitative methods based on counting the number of prezoosporangia per unit area and 
including the use of replicates were developed by Scott et al. (1985). The number of
prezoosporangia per unit weight after extraction from oyster tissue has also been used as a 
measure of infection intensity (Choi et al., 1989). More recently, a hemolymph assay has 
been developed for diagnosis. The "hemolymph technique", which is based on incubation 
of hemolymph in FTM, has the advantage of allowing for repeated diagnosis of the same 
individual without having to sacrifice the oyster (Gauthier and Fisher, 1990).
Despite recent developments that allow culture of the parasite continuously in vitro 
(La Peyre et al. 1993), the life cycle of P. marinus is still not well understood. The known 
life stages of P. marinus in oysters are: meronts (2-4 |im coccoid uninucleate cells), mature 
meronts (10-20 iim cells containing an eccentrically situated vacuole), and schizonts 
typically containing 8-32 merozoites (Perkins, 1988). These life stages have been 
extensively observed and described from live smears and oyster tissue sections using light 
(Mackin et al. 1950, Mackin 1951, Mackin and Wray 1952, Mackin 1962) and electron 
microscopy (Perkins 1966,1969,1976a, 1988). Based on those observations, the 
following sequence of events has been postulated. Immature meronts, also called 
merozoites, develop into meronts which then form multicellular schizonts by successive 
bipartitioning or progressive cleavage of the protoplasm. Subsequent rupture of the 
schizont releases immature meronts (Perkins 1976a, 1988). The rest of the life cycle, 
especially what happens outside the oyster is unclear.
It should be noted that incubation in FTM results in 15 |im to greater than 100 |xm 
enlarged cells called prezoosporangia or hypnospores, but these cells do not multiply and 
do not survive in FTM for more than 10 days (Perkins 1966,1988, Perkins and Menzel 
1966). Transfer of prezoosporangia into seawater, however, results in production and 
release of biflagellated zoospores from zoosporangia (Perkins 1966, Perkins and Menzel 
1966).
Perkinsus marinus zoospores have been shown to infect oyster tissue in laboratory 
experiments. Only light infections resulted even when tissues were exposed to millions of 
zoospores (Perkins, 1988). In contrast, heavy infections have easily been obtained by
exposing live oysters to tissue minces from infected oysters (Ray 1952, Mackin 1962). 
This suggests that meronts and not zoospores may be the primary infective cell type 
(Perkins, 1988).
Infections can be initiated in the gill, mantle, or gut epithelia, or in connective tissue 
near the basement membrane (Perkins, 1976b). Most initial infections have been observed 
in the digestive epithelium from the stomach to the rectum (Mackin, 1951). Early stages of 
infection are believed to occur in the hemolymph (Gauthier and Fisher, 1990). In fact, 
immature meronts have often been found within oyster hemocytes (Perkins, 1988). 
Parasites may grow and multiply within hemocytes or in the intercellular spaces of the 
hepatopancreas and gut (Mackin 1962, Perkins 1976b). Since oysters have an open 
circulatory system, it has been hypothesized that hemocytes phagocytize the pathogens and 
convey them all over the body (Mackin 1962, Andrews 1988a).
Advanced infections are characterized by abscesses of the epithelia, massive 
concentration of parasites throughout the connective tissue, and occlusion of hemolymph 
sinuses by parasites and hemocytes as well (Mackin 1951, Perkins 1976b). Rapid 
multiplication of the parasites results in destruction of hemocytes and tissues and usually 
causes death in about 1 month at 25-30 °C (Mackin 1962, Andrews 1988a).
Perkinsus marinus can be transmitted directly from oyster to oyster. Experimental 
infection in the laboratory is usually carried out by adding a few infected oysters to an 
aquarium where a group of about 25 uninfected oysters are maintained ("proximity 
method"), by adding minced tissue from infected oysters to the aquarium ("feeding 
method"), or by injecting a suspension of parasites in seawater into the mantle cavity of 
individual oysters ("injection method"). Comparison of these methods indicates that 
injection produces mortality in the shortest time (90% mortality in a group of 25 oysters in 
6 weeks) and also ensures simultaneous infections in the group. Injection, however, has 
the disadvantage of introducing another stress to the oysters. By the feeding method, 90% 
mortality occurs in about 9 weeks, but the additional stress is eliminated (Ray, 1954). The
proximity method is seldom used since it is more time consuming.
The effect of dosage of P. marinus infective cells on oyster mortality was studied 
by Mackin (1962) using the injection method. His work indicated that oysters (N = 25) 
receiving a single 1.0 mL injection containing 5 x 10^- 5 x 10^ parasite cells per oyster 
start to die after 3 weeks at a rate of 2% per day. Oysters injected with 5 x 1()3 cells start to 
die after 4 weeks at a rate of 0.3-1.0% per day, and oysters injected with less than 100 cells 
were not affected after 6 weeks when the experiment was terminated.
Andrews and Hewatt (1957) investigated the effects of low temperature on the 
establishment and progression of infections. Oysters injected with P. marinus extracted 
from infected tissues did not develop infections when maintained at temperatures lower 
than 15 °C for six weeks while oysters initially maintained at 28 °C for one week and 
subsequendy transferred to 15 °C conditions developed only light infections during the 
same period. Oysters held continuously at 28 °C for six weeks experienced 90% mortality.
Perkinsus marinus has proven to be extremely difficult to eradicate once it has 
invaded an area and no treatment for individual oysters is available. Low temperature and 
salinity have been shown to arrest infections, but not in a manner that could be applicable 
for treatment (Andrews 1988b). Unlike Haplosporidium nelsoni, which can be eliminated 
by a 2 week exposure to salinities of 10 ppt or less (Ford 1985), P. marinus persisted after 
8 weeks of exposure to salinities as low as 6 ppt (Ragone & Burreson 1993).
Control measures that could possibly prevent or reduce the impact of disease on 
oyster populations in Virginia include management strategies and breeding programs to 
increase oyster survival after exposure to disease agents. Andrews and Ray (1988) 
proposed management strategies for private oyster beds based on isolation of beds, 
harvesting early and cleaning beds, and closely monitoring disease. Implementation of 
such proposals, however, seems to be constrained by the potential risk of transmission of 
infections from contiguous public areas.
Breeding programs to increase oyster survival involve selecting surviving oysters
from disease endemic areas and breeding them over successive generations. Such an 
approach has been used successfully to increase survival of oysters exposed to H. nelsoni 
over eight generations of selection (Ford and Haskin 1987). Improvement in survival of 
oysters challenged with H. nelsoni, however, has not been correlated to particular cellular 
or humoral defense mechanisms of disease resistance (Ford 1986), but appears to result 
from an overall physiological superiority that makes cultured oysters more tolerant to the 
effects of disease (Myhre 1973). Stocks selected for increased survival when subjected to 
H. nelsoni challenge, however, have not attained increased survival when challenged with 
P. marinus suggesting that the physiological requirements of the two pathogens are 
different (Burreson, 1991a). A continuing effort to develop oysters with increased survival 
to P. marinus using native strains is underway at VIMS but it is unlikely that substantial 
progress can be made within a few years.
Another strategy to circumvent disease affecting oysters in the Chesapeake Bay 
would be to introduce another oyster species more resistant and/or tolerant to diseases than 
C. virginica. The proposed introduction of C. gigas has been considered by Mann et al. 
(1991). Arguments that support the proposed introduction of C. gigas are based on results 
from laboratory challenges with P. marinus that showed a lower prevalence and intensity of 
infections and lower oyster mortality in C. gigas than in C. virginica (Meyers et al. 1991). 
Proposals to introduce C. gigas in the Chesapeake Bay, however, are controversial due to 
potential parallel introduction of foreign disease agents and/or displacement of local biota, 
including extant C. virginica populations, by C. gigas. Nevertheless, carefully controlled 
introduction of C. gigas for research is possible and has recently been effected in Virginia 
for challenge studies with H. nelsoni and P. marinus following the proposal of Mann et al. 
(1991).
Chemotherapy, the focus of this study, is another approach that could be used to 
control P. marinus infections in oysters. Applications of this approach would include 
treatment of seed and broodstock oysters as well as oysters held in trays or aquaria for use
in aquaculture and research. To date, there have been only two studies that explored the 
effects of chemotherapeutants on P. marinus. At a time when the parasite was classified as 
a fungus, Ray (1966a) examined the effects of 12 antifungal antibiotics on P. marinus- 
infected oyster tissue. Initially, antifungal agents were directly added to FTM containing 
pieces of infected tissues. Compounds that markedly inhibited P. marinus enlargement at 
concentrations of 50 mg/L or less were further tested by adding them to autoclaved sea 
water aliquots containing infected oyster tissues. At weekly intervals, pieces of gill tissue 
were checked for ciliary activity and then tissues were rinsed in sterile seawater and 
transferred for incubation in FTM. Among the 12 compounds tested, only cycloheximide 
and to a lesser extent streptimidone, which is structurally related to cycloheximide, were 
effective when added to FTM or seawater cultures at concentrations ranging from 10 to 50 
mg/L.
The results presented above prompted Ray (1966b) to expose P. marinus-infected 
oysters to cycloheximide baths in seawater of 25 ppt and 25 °C. In a first experiment, 
oysters were exposed to 1- 50 mg/L cycloheximide baths renewed weekly for periods of 45 
to 164 days. In a second experiment, oysters were exposed to a 10 mg/L cycloheximide 
bath for 30 days (renewed weekly). In the first experiment, prevalence (collectively for all 
treated oysters), declined from 70% before treatment to 50% after treatment. In the second 
experiment, weighted prevalence declined from 3.00 before treatment to 1.25 after 
treatment. In both experiments, survival was greater for treated oysters than for untreated 
oysters. In the first experiment, there was 100% survival of treated oysters and only 20% 
survival of untreated oysters after 90 days of treatment. In the second experiment, there 
was 93% survival of treated oysters and 70% survival of untreated oysters after 28 days of 
treatment A trend of increased survival with increasing concentrations and longer 
exposure time was reported. Furthermore, the intensity of the infections appeared to be 
lower as treatment time increased. Treatment appeared to arrest mortalities associated with 
moderate-heavy infections. In addition, infection intensities seemed to be reduced during
treatment, although they may have later relapsed. Conclusions were limited because 
sample sizes were small (N = 5 in most cases), and no statistical analysis was performed 
on the data.
Other studies on the effects of chemicals on P. marinus include Scott et al. (1985) 
who found that exposure of infected oysters to a combination of low salinity and 
chlorine-produced oxidants (CPO) significantly decreased P. marinus related mortalities as 
compared to untreated controls held at low salinities. In vitro studies by Goggin et al. 
(1990) indicate that Perkinsus spp. prezoosporangia free of host tissue die within 30 
minutes when exposed to chlorine solutions of 6 ppm or higher.
Since the work of Ray in 1966, there have been several developments that allowed 
for re-examination of the effects of chemotherapeutants on the oyster pathogen P. marinus. 
The referred developments include ultra structural studies of P. marinus leading to the 
present classification of the parasite within the Apicomplexa, extension of the thioglycollate 
method to diagnose P. marinus-'mfected hemolymph, and the recent formulation of a 
medium that supports P. marinus cultures, as previously mentioned. In addition, 
anticoccidials of wide use against avian coccidiosis have more recently been recommended 
for use in fish (Meyer & Schnick 1989).
Criteria to select chemotherapeutants for the present investigation included prior 
information concerning efficacy against P. marinus, efficacy against parasites 
taxonomically related to P. marinus, use on and toxicity to aquatic organisms and food 
animal species, water solubility, mode of chemical action, availability and cost Similar 
criteria have been used before to select chemicals for investigations on control of parasitic 
diseases (Griffin 1989). It was very difficult to identify compounds that met all or most of 
the aforementioned criteria, but there was at least one reason to include each compound 
chosen.
Very little information could be found on the use of antifungals and anticoccidials in 
marine organisms. Disease control research in freshwater aquaculture has been conducted
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for several decades but advances in understanding and control of disease in marine 
aquaculture is recent, largely within the last 20 years. Reports on chemotherapy of marine 
organisms are mostly restricted to bacterial diseases affecting finfish, crustaceans, and 
larval stages of bivalves (Sindermann & Lightner 1988). Moreover, treatments for internal 
infections in aquatic organisms, including freshwater ones, are not well established (Meyer 
& Schnick 1989). Therefore, background information for the present study was mostly 
limited to freshwater or terrestrial organisms.
Considering the new classification of P. marinus within the Apicomplexa, and the 
fact that chemotherapeutants have been widely developed against coccidian parasites in 
poultry, the following anticoccidial compounds were selected. Amprolium, arprinocid, and 
sulfadimethoxine were selected because they are fairly safe anticoccidial agents. 
Sulfadimethoxine has also been used in fish as antibacterial agent The latter compounds 
have been without adverse effects even when administered at several times their therapeutic 
dose in poultry or fish (McDougald 1982, Maestrone et al. 1984). The water solubility of 
sulfonamide compounds, which include sulfadimethoxine, has made them more useful for 
treatment of established infections than other less water soluble compounds. The mode of 
action of sulfadimethoxine, amprolium, and arprinocid is by competitive inhibition of 
metabolites leading to the formation of vitamins and nucleic acids. Sulfadimethoxine is an 
antagonist of para-aminobenzoic acid (PABA) which is involved in the formation of amino 
acids. Amprolium is a partially water soluble analog of the vitamin thiamine, and 
arprinocid blocks formation of nucleic acids (McDougald 1982, Gutteridge and Coombs
1977). Chemical structures of anticoccidial and antifungal compounds used in this study 
are given in Appendix A.
Unlike the anticoccidial agents described above, the polyether ionosphores lasalocid 
and monensin are not water soluble and have a narrow margin of safety. In embryonic 
chick kidney cell cultures inoculated with Eimeria tenella sporozoites, monensin was toxic 
to kidney cells at concentrations ranging from 100 mg/L to less than 1 mg/L and was active
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against E  tenella sporozoites at concentrations lower than 0.1 mg/L (Strout & Ouellettte 
1973). The LD50 for monensin ranges from 2 mg/kg in horses to 185 mg/kg in chickens 
(McDougald 1982). Despite their narrow margin of safety and their mediocre performance 
in laboratory tests, polyether antibiotics including lasalocid and monensin, have shown 
results superior to other compounds when tested under field conditions. Efficacy and 
toxicity of polyether ionosphorus antibiotics is related to their ability to disrupt the selective 
permeability of membranes (McDougald 1982,1990).
Toltrazuril, a synthetic anticoccidial compound developed in Europe, has also 
shown considerable activity against coccidians. microsporidians, and myxozoan parasites 
of fish and insects (Melhom et al. 1988, Schmahl et al. 1989). Toltrazuril, however, could 
not be used in the present study because it is not available in the U.S. market.
Based on Ray's (1966 a,b) success with cycloheximide, it as well as the other 
antifungal agents were selected. Cycloheximide and malachite green were included even 
though they are potentially harmful to human health or non-target organisms (Bower 1989, 
Meyer & Schnick 1989). They have been successfully used against various aquatic 
pathogens and therefore constitute good reference standards. In addition to the use against 
P. marinus, cycloheximide has been used to control Labyrinthuloides haliotidis, a pathogen 
of juvenile abalone (Bower, 1989). Bower found that exposure of infected abalone to 1 
mg/L of cycloheximide for 5 consecutive days reduced infection prevalence and abalone 
mortality. No lethal effects on abalone survival were reported after a 10 day exposure to 
100 mg/L of cycloheximide.
In vitro exposure of yeasts, fungal pathogens of man, and bacteria to cycloheximide 
by Whiffen (1948) showed that cycloheximide is highly active against certain yeasts and 
fungal pathogens. Among the yeasts and fungal pathogens exposed to cycloheximide by 
Whiffen, Cryptococcus neoformans, Nematospora phaseoli, Pichia membranaefasciens, 
several species of Saccharomyces and other yeasts species were inhibited by concentrations 
of less than 1 mg/L. None of the tested bacteria were inhibited when exposed to
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cycloheximide concentrations as high as 1000 mg/L. Median lethal dose of cycloheximide 
by intravenous injection ranged from 2.7 mg/kg in rats to 150 mg/kg in mice (Whiffen 
1948).
Malachite green was included because it has been the most extensively used external 
parasiticide of aquatic organisms (Meyer & Schnick, 1989). It is an aryl-methane dye with 
wide antimicrobial activity against bacteria, fungi, and protozoa. Aryl-methane dyes are 
particularly active against Gram-negative bacteria, and also against oomycete fungi 
responsible for saprolegniasis in freshwater fish and other fungal infections in marine 
Crustacea (Alderman 1985). The use of malachite green as an internal chemotherapeutant, 
however, has not been widely investigated. Exposure of rainbow trout to 1.5 mg/L of 
malachite green for 1 day prevented the development of proliferative kidney disease (PKD) 
Clifton-Hadly & Alderman (1987). Acute toxicity of malachite green to freshwater 
invertebrates, as reported by Bills et al. (1977), varies from 0.51 mg/L -122 mg/L. 
Malachite green is a respiratory enzyme poison known to destroy mitochondria (Alderman 
1985). In addition to its destructive action against mitochondria, malachite green is known 
to be teratogenic in laboratory animals, and its use in aquaculture in the US has therefore 
not been approved by FDA (Meyer & Schnick 1989).
Despite the fact that malachite green is known to cause adverse effects, it is still 
used as a reference standard against which new antifungal agents are compared. In an 
effort to find a substitute for malachite green to treat saprolegnial fungi infecting fish,
Bailey and Jeffrey (1989) tested cycloheximide, amphotericin-B, ketoconazole, 5- 
fluorocytosine, as well as 200 or more other antifungal agents on two species of 
Saprolegnia ,in vitro, and on infections in rainbow trout eggs. Minimum inhibitory 
concentrations and toxicity to eggs were determined in short term exposures (< 1 h r ). 
Cycloheximide showed moderate antifungal activity in vitro but was toxic to eggs at 
exposures of 25 mg/L. In vitro exposures to > 1000 mg/L of amphotericin-B or 300 mg/L 
of ketoconazole had low antifungal activity. Toxic effects of amphotericin-B and
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ketoconazole, however, were not reported. In Bailey and Jeffrey's paper, 5-Fluorocytosine 
was referred to as being either ineffective, toxic to non-target organisms, or otherwise 
unsuitable for further testing. No further details were given, however, to ascertain the 
specific reason for removing 5-Fluorocytosine from further testing. Exposure of infected 
eggs to S mg/L of malachite green was effective without causing acute mortality to eggs.
Amphotericin-B has been effective in treatment of systemic mycosis in humans and 
domestic animals. Grayson (1982) reported that amphotericin-B was active in vitro against 
pathogenic yeasts at concentrations of 0.01-2.0 mg/L. Its activity against opportunistic, 
subcutaneous and dermatophytic fungi was less, 3.12-30 mg/L. The mode of action of 
amphotericin-B is by preferentially binding to sterol components in the membranes of 
fungi. The LD50 in laboratory animals ranges from 4-6 mg/kg by intravenous 
administration to > 8000 mg/kg by oral administration. Systemic mycosis caused by fungi 
of the genera Aspergillus, Blastomyces, Candida, Cryptococcus, and Histoplasma can be 
controlled by amphotericin-B (Deacon 1984). Similar to amphotericin-B, ketoconazole 
interferes with membrane function in fungi by blocking the synthesis of ergosterol. The 
LD50 of ketoconazole ranges from 210 mg/kg in rats to > 900 mg/kg in dogs by oral 
administration (Janssen 1989). 5-fluorocytosine has been used against yeast infections 
caused by Candida albicans and Cryptococcus neoformans, but it has little effect against 
other mycotic fungi. Its mode of action is by interfering with RNA and protein synthesis in 
fungi. It is almost completely non-toxic to mammals (Deacon 1984, Merck & Co. 1986).
Two other compounds were selected for in vitro testing. Fumagillin has shown 
significant activity on preventing development of Pleistophora sp., a microsporidian 
parasite of eels (Kano et al. 1982). Cimetidine inhibits gastric acid secretion and is used as 
an anti-ulcerative (Merck & Co. 1989). It should be noted that arprinocid, lasalocid, 
monensin, and potentiated sulfadimethoxine are almost insoluble in water. Therefore, the 
use of a solvent is necessary. Dimethyl sulfoxide (DMSO) has been used successfully to 
dissolve anticoccidial agents, and, provided that its final concentration was less than 1.0%,
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it did not interfere with parasite development or host cell integrity (Ryley and Wilson, 
1976). Furthermore, toxicity tests on several species of fish showed that more than 3% of 
DMSO is required to produce mortality in a 96h test (Willford, 1968).
Methods to search for chemotherapeutants in animals have largely relied on 
empirical testing. Theoretical models that relate the structure of a chemical to its biological 
activity have been developed, but their role in drug discovery has been minimal.
Therefore, in vitro and in vivo tests are still the preferred methods for detection of 
antiparasitic activity (Lichtfield 1958, Schnitzer and Hawking 1963, Ryley and Wilson 
1976, Grayson 1982). The objective of in vitro and in vivo is to detect antiparasitic activity 
of compounds at levels non toxic to the host. In the long term, effective compounds are 
expected to produce no side effects on the host and to be purged or removed prior to 
harvest when the animal is used for human consumption.
Based on Ray's results with antibiotic antifungal agents and considering the new 
classification of P. marinus within the Apicomplexa I hypothesized that antifungal and/or 
anticoccidial compounds would be acdve against P. marinus and could possibly be used to 
control established infections in oysters. It was reasonable to expect that anticoccidial 
compounds would be effective in controlling P. marinus infections, since P. marinus has 
recendy been classified within the phylum Apicomplexa, which contains coccidians (Levine
1978). Given that several anticoccidial agents have already been approved by the Federal 
Drug Administration (FDA) for use in poultry, their registration for use in aquaculture 
would be facilitated (Meyer & Schnick, 1989).
The experimental approach of the present investigation was to test chemicals against 
P. marinus-Mected hemolymph and cultured P. marinus cells (in vitro experiments), and 
against infections in oysters (in vivo experiments). Since there very little information was 
found on recommended doses of anticoccidial agents for treatment of aquatic organisms 
(particularly bivalves), the in vivo studies included a toxicity experiment to determine 
possible lethal concentrations to oysters. Perldnsus cell cultures and most antifungal agents
only became available towards the end of the investigation. Therefore, initial experiments 
focused on anticoccidial agents and testing in vitro was accomplished on infected 
hemolymph whereas later experiments focused on antifungal agents using P. marinus 
cultures preferentially for later in vitro tests.
METHODS
In vitro experiments
The first in vitro experiments consisted of adding hemolymph from P. marinus- 
infected oysters to chemical baths containing 100 mg/L of active ingredients of 
amprolium, arprinocid, cycloheximide, lasalocid, malachite green, monensin, 
sulfadimethoxine, and potentiated sulfadimethoxine for one day. If 100 mg/L baths 
significantly inhibited the number of parasite cells enlarging to the prezoosporangia 
(hypnospore) stage, infected hemolymph was then exposed to 10 mg/L, 1 mg/L, 0.1 
mg/L, and 0.01 mg/L baths during a subsequent experiment. Amphotericin-B was tested 
in a separate trial at 100 mg/L, 10 mg/L and 1 mg/L.
This methodology was based on the hemolymph technique (Gauthier & Fisher 
1990), modified to test the effects of chemicals on parasite cells (Table 1). Oyster shells 
were notched adjacent to the adductor muscle, using a lapidary saw. Infected hemolymph 
was withdrawn with a syringe from the adductor muscle sinus of at least 10 oysters 
(selected from a heavily infected group) until a 10 mL stock was obtained. After mixing 
the stock by vortex, 0.2 mL aliquots were dispensed into 1.5 mL microcentrifuge tubes. 
Infected hemolymph aliquots were then exposed to 1 mL chemical baths for one day at 
room temperature (20°C). After exposure to chemical baths, hemolymph aliquots were 
centrifuged at 265 x g for 15 minutes to concentrate parasite cells in pellets; cell free 
serum was discarded. The pellets, containing merozoite, meront and schizont stages of 
the parasite, were further washed once in 0.22 |im-filtered York River water (FYRW) at 
23 ppt salinity and resuspended in 1 mL FTM containing 0.05 mL of penicillin and 
streptomycin (2500 units/mL). The inoculated media was incubated at 25 °C in the dark 
for 5-7 days, then samples were centrifuged at 265 x g for 15 minutes and the supernatant 
was discarded. Pellets were resuspended in 1 mL 2 M NaOH for 15 minutes and then
washed twice in distilled water. Pellets were stained with 2 drops of Lugol’s iodine 
working solution (Gauthier & Fisher 1990). After staining, the volume of each sample 
was raised to 1 mL with distilled water and dispensed into separate wells of a 24-well 
tissue culture plate. Enumeration of the total number of recognized prezoosporangia per 
well was made on an inverted scope at 100 X magnification. Criteria to identify 
prezoosporangia included size, color, and overall appearance. In general, coccoid cells 
greater than 6 |im in diameter and/or mostly blue in color were recognized as 
prezoosporangia.
Chemical baths containing amprolium, sulfadimethoxine, cycloheximide, or 
malachite green were freshly prepared by dissolving 10 mg of the chemical in 10 mL 
FYRW at 23 ppt salinity and then serially diluting to the desired concentration. When 
amphotericin-B, arprinocid, lasalocid, monensin, and potentiated sulfadimethoxine were 
used, 10 mg of the chemical was first added to 1 mL of dimethylsulfoxide (DMSO), 
thoroughly mixed using a vortex blender, and then diluted in FYRW at 23 ppt salinity.
The experimental design consisted of triplicate treatments and included an 
untreated control group, and a solvent control group tested at 1% DMSO (the highest 
concentration of solvent used). Since Amphotericin-B became available at a later stage, 
it was tested separately using a new set of solvent and untreated controls. Therefore, 
results for Amphotericin-B on infected hemolymph are presented separately. A one-way 
ANOVA was used to examine differences in mean number of cells between treatments. 
When significant F-ratios were detected, a Dunnett’s test was performed to examine the 
data for differences between individual treatments and controls.
Table 1. Flow chart of methods for in vitro experiments with infected hemolymph. Note: 
In the hemolymph technique (Gauthier & Fisher 1990), hemolymph is withdrawn from 
individual oysters to assess P. marinus infections. In the present technique, hemolymph 
was pooled from several oysters (> 10) and exposed to treatment prior to incubation in 
FTM to test for chemical effects.
Mix and divide into 0.2 mL aliquots
Rinse in FYRW and incubate in FTM
Expose to 1 mL chemical baths for 1 day
Count No. prezoosporangia per well(lOOX)
Compare untreated controls to treated groups
Stain and transfer prezoosporangia to microtiter wells
Collect and pool 10 mL hemolymph from infected oysters
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In addition to experiments in which hemolymph was used as a source for P. 
marinus, other in vitro experiments involved testing chemicals on cultured-P. marinus 
cells (Table 2). Stocks of the serologically identified Perldnsus marinus isolate; 
Perkinsus-1 was supplied by Dr. J. F. La Peyre at VIMS and maintained in 35 cm^ tissue 
culture flasks (Coming Glass Works, Coming NY) in 22 ppt JL-ODRP medium at 28°C 
(La Peyre et al., 1993). Cell density in stock cultures was 5 x 10^ cells/mL. In all 
experiments, log-phase cultures were used.
Aliquots containing approximately 10^ cells were removed from stock cultures 
with a micropipette and exposed for 1 day to 1 mL chemical solutions in 1.5 mL 
microcentrifuge tubes. After exposure to chemical baths, treated cells were centrifuged at 
265 x g for 15 minutes to concentrate cell pellets and the supernatant was discarded. 
Pellets were rinsed once in 22 ppt artificial seawater (ASW) and incubated in FTM as in 
the previous experiment. ASW was prepared by dissolving seawater synthetic basal salt 
mixture (Sigma Chemical Co.) in distilled water. After incubation, pellets were placed 
on 24 well tissue culture plates. Prezoosporangia were counted from 3 replicate fields at 
100 X in each of three replicate wells. Cell diameter was measured at 320 X on 25 
haphazardly selected cells in each replicate.
In a separate assay, cells were tested for viability after exposure to chemicals. 
Instead of using microcentrifuge tubes, cells were seeded directly on 24 well plates and 
exposed to 1 mL chemical baths for 1 day. Then, 0.10 mL of neutral red stain (0.05%) 
was added to each well. Neutral red is a vital stain. Live cells uptake the stain while dead 
cells do not. After 15 minutes, stained and unstained cells were counted at 320 X using 
an inverted microscope. Counts were made on 2 replicate fields in each of two wells.
The choice of using prezoosporangia abundance and size as endpoints of chemical 
activity was based on the prior use of inhibition of prezoosporangia enlargement as an 
indicator of anti-P. marinus activity by Ray (1966a). Other possible endpoints such as 
zoospore formation could have been used on non-cultured cells but development of
zoospores in the laboratory has not been consistently achieved. Viability was selected as 
an endpoint because the procedure for its determination has been well established and is 
reliable, and because cytocidal effects could be expected at least from those compounds 
that disrupt membrane function such as amphotericin-B, lasalocid, and monensin.
Eight chemicals (amphotericin-B, cimetidine, cycloheximide, 5-fluorocytosine, 
fumagillin, ketoconazole, lasalocid, and monensin) were tested on cultured-P. marinus 
cells. In addition, there was a solvent control (1% DMSO) and a 22 ppt ASW control.
All compounds were dissolved in DMSO by dissolving 10 mg of each chemical in 1 mL 
DMSO and mixing with a vortex. The 22 ppt ASW was added to bring the final volume 
to 10 mL. The resulting solution was diluted in ASW until the concentration of the 
chemicals was 100 mg/L and the concentration of the solvent was 1% . Lasalocid and 
monensin were tested at a later stage than the other compounds. Therefore, results for 
lasalocid and monensin are presented separately. A list of compounds tested on infected 
hemolymph (prior experiment) and on cultured cells (this experiment) is provided in 
appendices B and C.
Table 2. Flow chart of methods for in vitro experiments with cultured-P. marinus cells.
or Rinse and incubate in FTMStain with Neutral Red and count
Expose to 1 mL chemical baths for 1 day
Count and measure prezoosporangia (100X)
Stain and transfer prezoosporangia to microtiter wells
Seed microtiter wells or microcentrifuge tubes with 105 cells
Compare untreated controls to treated groups
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T oxicity experim ent
For this experiment, P. marinus-free oysters (70 mm mean shell height, 32 gm 
mean whole weight) were obtained from the Wye River in Maryland in May 1991. After a 
2 week acclimation to 25°C and 17 ppt in 1.0 |im FYRW, a sample of 25 oysters was taken 
for diagnosis of P. marinus in a combined sample of rectal, gill, and mantle tissue taken 
from each oyster following the method of Ray (1952). Subsequently, the remaining 
oysters were randomly assigned to aquaria for exposure to chemical baths.
The experimental design consisted of duplicate treatments of 5 oysters per 10 L 
bath. Oysters were exposed to baths of amprolium, arprinocid, lasalocid, monensin, 
potentiated sulfadimethoxine, or sulfadimethoxine at four concentrations: 0.01 mg/L, 0.1 
mg/L, 1 mg/L, and 10 mg/L. In addition, there were 2 control baths-one untreated control 
and one solvent control at 0.1% DMSO. Each bath was renewed daily for 4 days. Stocks 
of chemical solutions were freshly prepared each day by adding 100 mg of active 
ingredients to 10 mL of DMSO, thoroughly mixing using a vortex blender, and adjusting to 
the desired concentration by dilution in FYRW. Sulfadimethoxine, a highly water soluble 
compound, was dissolved directly in FYRW.
Oysters were fed a daily radon of diatoms (Chaetoceros calcitrans and Thallasiosira 
pseudonana) and/or flagellates (Isochrysis galbana) at an approximate concentration of 5 x 
10® to 5 x 10^ cells/L. Chemical solutions were dispensed into aquaria, following the 
addition of food. Aeration was continuously provided to aquaria. Aquaria were inspected 
daily at the time of water change for dead oysters. Oysters that remained open after the 
tanks were emptied for water exchange were considered dead. When appropriate, the 
concentration of exposure associated with a 50% mortality at 96 hr (LC50) was estimated 
by graphic and binomial methods (Gelber et al. 1985).
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In vivo experiments
There were 3 experiments designed to determine the effect of chemicals on P. 
marinus infections in oysters. Experiment 1 was designed to determine the effect of 4 day 
chemical baths on preventing infections (Table 3). Adult oysters (>50 mm shell height) 
were obtained from the Wye River in Maryland, in August 1991, cleaned of fouling 
organisms, and acclimated to 25“C and 20 ppt in 1 pm FYRW for one week. Then, FTM 
tissue diagnosis for P. marinus was performed, as previously described, on 25 oysters. 
The remaining oysters were randomly assigned to 25 L aquaria in groups of 25. Treatment 
consisted of 4 day static renewal baths of 0.1 mg/L of amprolium, arprinocid, lasalocid, 
monensin, potentiated sulfadimethoxine, and 10 mg/L of sulfadimethoxine. There were six 
treatments (one for each chemical) and three controls (untreated unchallenged, untreated 
challenged, solvent challenged) all tested in duplicate. Chemicals were prepared and added 
to aquaria, as in the toxicity experiment In the present experiment however, amprolium 
(which is 20% water soluble) was directly dissolved in water without previous dissolution 
in DMSO. The final concentration of DMSO in exposure media was kept below 0.1%.
Following exposure to chemicals, oysters (N = 25) were challenged to daily 
consecutive doses of 1 x 10? P. marinus cells per 25 L aquarium for 2 consecutive days. 
To obtain parasite cells for challenge, tissues from 20 oysters (selected from a source 
showing 100% prevalence), were minced in a blender with 250 mL of 0.22 FYRW and 
then filtered through a 300 pm, 75 pm, 53 pm, and 20 pm sieve set. Parasite cell 
abundance was estimated as follows from three 1-mL subsamples taken from the resultant 
suspension. Each subsample was incubated in 10 mL FTM containing 0.5 mL of penicillin 
and streptomycin at 25 °C in the dark for 1 day. After incubation, samples were 
centrifuged at 265 x g for 15 minutes to discard the FTM supernatant. Pellets, containing 
parasite cells, were washed twice in distilled water and resuspended in 1 mL distilled 
water. Aliquots of the resulting cell suspensions were then counted using a
hemocytometer, and then the stock suspension was adjusted to yield the desired 
concentration.
Oysters were fed an algae diet in aerated aquaria as in the previous experiment. 
Water was maintained at acclimation conditions throughout the experiment and changed 
once a day. Six weeks after challenge, all oysters were sacrificed and diagnosed for 
disease as before. Prevalence was calculated by dividing the number of infected oysters by 
the total number of oysters diagnosed for each treatment replicate. Infection intensity in 
tissue samples was determined as described by Mackin (1962) and categorized as negative, 
light, moderate, or heavy. To calculate weighted prevalence, the following code numbers 
were assigned to the intensity (I) categories: 0 = negative, 1 = light, 3 = moderate, and 5 = 
heavy (Paynter & Burreson 1991). Weighted prevalence was calculated as the average 
value of infection intensity for number of oysters diagnosed in the treatment replicate (X 
Ini/N). Where Ini = sum of prevalences for each intensity category, and N = total number 
of oysters diagnosed. Differences in average prevalence and weighted prevalence between 
treated and untreated groups were examined by one way ANOVAs.
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Experiment 2 was conducted to determine if amprolium, cycloheximide, malachite 
green, and/or sulfadimethoxine baths were effective in reducing P. marinus infections in 
oysters (Table 4). Adult oysters (>50 mm shell height), were collected from Point of 
Shoals in the James River in September 1992, cleaned of fouling organisms, individually 
labeled using a water proof marker, and subsequently maintained in a static tank filled with 
1.0 (im FYRW at 20°C and 20 ppt for one week. Water was renewed daily. During that 
time, 0.3 mL hemolymph samples were withdrawn from each oyster and diagnosed for P. 
marinus following the hemolymph technique (Gauthier & Fisher 1990).
One hundred and eighty oysters, most with light infections, were selected and 
randomly assigned to 10 L aquaria in groups of ten. Concentrations of chemical baths 
ranged from 100 mg/L to 1 mg/L. Compounds considered non toxic to oysters, namely 
amprolium and sulfadimethoxine, were applied as 100 mg/L and 10 mg/L baths. 
Cycloheximide and malachite green were applied as 10 mg/L and 1 mg/L baths. Since 
oysters did not survive exposure to 10 mg/L or 1 mg/L of malachite green, another 
experiment was setup to test that compound at 0.1 mg/L and 0.01 mg/L.
All baths, including untreated controls, were tested in duplicate. Stock solutions of 
the chemicals were prepared immediately prior to use by adding 10 mg, 100 mg, or 1000 
mg of active ingredients to 10 mL of FYRW in 50 mL centrifuge tubes. Thorough mixing 
was accomplished with a vortex blender. All compounds tested in this experiment were 
directly dissolved in FYRW. Daily rations of microalgae suspensions were added to each 
tube until the volume was raised to 50 mL. Then, the chemical-algae suspension was 
mixed as before and added to aquaria every other day for 2 weeks.
Dilution water consisted of 1.0 |lm-FYRW with a salinity of 22 ppt warmed to 
20°C. Aeration was provided continuously. Aquaria were covered with sheets of 
Plexiglas to avoid possible loss of chemicals at the air interface. Water was changed prior 
to addition of chemicals. On days when chemicals were not added to aquaria, oysters were 
fed an algae diet as in the previous experiment
After the 2 week treatment, P. marinus diagnosis was performed on a second 
hemolymph sample and on a tissue sample taken from each oyster. Tissue samples were 
assayed for P. marinus in FTM as previously described. Only tissue diagnosis was 
performed on oysters exposed to the lower concentrations of malachite green during the 
follow-up experiment
Log transformed prezoosporangia count data was examined by a repeated measure 
ANOVA. If the ANOVA indicated significant differences, a Dunnett’s test followed to 
identify treatments that differed from controls. In addition, a paired t-test was used to 
compare pre-treatment and post-treatment abundance's of P. marinus cells in the 
hemolymph samples of oysters from selected treatments. Differences in log transformed 
weighted prevalence between treatments were examined by a one way ANOVA. For ail 
statistical tests alpha was set at 0.05.
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In experiment 3, the effect of a 30 day cycloheximide exposure on P. marinus 
infections in oysters was examined. In addition, the subsequent progression of infections 
was monitored for 30 days after treatment (Table 5). Two hundred and fifty oysters (66 ± 
7 mm mean shell height) were collected from Point of Shoals in the James River in 
November 1992, cleaned and 25 oysters were sacrificed for P. marinus diagnosis. A 
second diagnostic sample was taken after 10 days of acclimation to 20°C and an ambient 
salinity of 20 ppt. The diagnosis was performed on a combined tissue sample as 
previously described. Subsequently, the remainder of the oysters were labeled and 
randomly assigned to one of four treatments: 30 day exposure to 10 mg/L cycloheximide 
bath, 30 day untreated control, 30 day exposure to 10 mg/L cycloheximide followed by 30 
days without treatment, and 60 day untreated control. All treatments were tested in 
duplicate 25 L aquaria containing 25 oysters each. Chemicals were mixed with algae and 
added to aquaria, as in experiment 2, for 30 days. Oysters were fed an algae diet, and 
aeration was provided, as in previous experiments. Dilution water consisted of 1.0 pm- 
FYRW with an ambient salinity ranging from 16 to 20 ppt heated to 20°C. Aquaria were 
covered as in the previous experiment. Disease prevalence and intensity were determined, 
as described before, for all treatment replicates at 30 days and 60 days. The effects of 
treatment and time on transformed prevalence and transformed weighted prevalence were 
examined by two way ANOVAs.
Statistical Analysis
For statistical analysis of results from in vitro and in vivo experiments, data were 
transformed, if necessary, following Gagnon et al. (1989). Prezoosporangia count data 
and weighted prevalence data were log (x+1) transformed, and prevalence(%) was arcsin 
transformed. Normality was examined by the Kolmogorov-Smimov test, and 
homogeneity of variance by the Cochran and Bartlett/Box tests, using SPSS^ software 
(SPSS Inc. 1986). Data used for subsequent analysis were normal and homogeneous at a
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confidence level above 90% (Appendices D and E). ANOVA, Dunnett, and t-tests were 
performed using SuperAnova software (Gagnon et al. 1989). Only one control group, 
either untreated control or solvent control, was included in the statistical analysis depending 
on which gave the more conservative results.
Source of chemicals
Amphotericin-B, cycloheximide, and 5-fluorocytosine were obtained from Sigma 
Chemical Company, St. Louis, MO; Amprolium from MSD-AGVET, St. Louis, MO; 
cimetidine from SmithKline Beecham Pharmaceuticals, King of Prussia, PA; ketoconazole 
from Research Diagnostics Inc., Flanders, NJ; lasalocid, sulfadimethoxine, and potentiated 
sulfadimethoxine from Roche Vitamins and Fine Chemicals, Nutley, NJ; lasalocid, 
monensin, and arprinocid from Lilly Research Laboratories, Greenfield, IN; and malachite 
green from Argent Chemical Laboratories, Redmond, WA.
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RESULTS
In vitro experiments
In experiments using infected hemolymph as a source of P. marinus cells, there 
was a significant (P = 0.000) effect of exposure to 100 mg/L on prezoosporangia 
abundance. Six chemicals, amphotericin-B, cycloheximide, lasalocid, malachite green, 
monensin, and sulfadimethoxine, yielded significantly lower (P < 0.05) prezoosporangia 
abundance than the untreated control group or the solvent control group (Fig. 1 and 
Tables 6 and 7 A). Average prezoosporangia abundance decreased from 387 cells in the 
untreated control group to less than 10 cells in the cycloheximide, lasalocid, and 
malachite green groups respectively (Table 8 ); and from 413 cells in the untreated 
control group to less than 1 cell in the amphotericin-B group (Table 7B).
At 10 mg/L exposure, there was also a significant (P = 0.000) effect of treatment 
on prezoosporangia abundance (Fig. 2 and Tables 7A and 9). At this concentration, 
amphotericin-B, lasalocid, and malachite green treatments had significantly (P < 0.05) 
lower prezoosporangia abundance than the untreated control group. Average 
prezoosporangia abundance decreased from 83 cells in the untreated control group to less 
than 3 cells in lasalocid and malachite green groups respectively (Table 10) and from 413 
cells in the untreated control group to 25 cells in the amphotericin-B group (Table 7B).
At concentrations lower than 10 mg/L, the effect of treatment on prezoosporangia 
abundance was not significant (P > 0.05).
Figure I. Mean abundance of prezoosporangia in infected hemolymph samples after 
exposure to 100 mg/L chemical treatments. Abbreviations: UC = untreated control, SC = 
solvent control, AMP = amprolium, ARP = arprinocid, CYC = cycloheximide, LAS = 
lasalocid, MG = malachite green, MON = monensin, PSUL = potentiated 
sulfadimethoxine, SUL = sulfadimethoxine. Bars = means of 3 replicate 0.2 mL 
hemolymph samples. Error bars = standard errors. * = significantly lower (p < 0.05) than 
untreated control.
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Table 6. One way ANOVA and Dunnett tests describing the effect of 100 rag/L chemical 
treatments on mean prezoosporangia abundance in infected hemolymph samples. 
Significance level = 0.05.
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatment 8 21.080 2.635 26.758 0.000
Residual 18 1.773 0.098
Dunnett’s test for mean < control. Critical difference = 0.661.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Lasalocid -2.200 significant
Malachite green -2.200 significant
Cycloheximide -2.073 significant
Monensin -1.508 significant
Sulfadimethoxine -0.724 significant
Amprolium -0.599 not significant
Arprinocid -0.228 not significant
P. sulfadimethoxine -0.031 not significant
Table 7A. One way ANOVA and Dunnett tests describing the effect of amphotericin-B 
treatments on mean prezoosporangia abundance in infected hemolymph samples. 
Significance level = 0.05.
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatm ent 4 14.081 3.520 158.229 0.000
Residual 10 0.222 0.022
Dunnett’s test for mean < control. Critical difference = 0.301.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Amphotericin-B (100 mg/L) -2.427 significant
Amphotericin-B (10 mg/L) -1.112 significant
Amphotericin-B (1.0 mg/L) -2.073 not significant
Amphotericin-B (0.1 mg/L) -1.508 not significant
Table 7B. Mean abundance of prezoosporangia in infected hemolymph samples after 
exposure to amphotericin-B treatments. Values indicate average of three replicate counts 
per 0.2 mL pooled hemolymph sample. Standard deviation in parenthesis.
PREZOOSPORANGIA ABUNDANCE
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 413.67 (97.76) 2.61 (0.11)
Solvent control 356.00 (148.01) 2.53 (0.18)
Amphotericin-B (100 mg/L) 0.33 (0.57) 0.10(0.17)
Amphotericin-B (10 mg/L) 25.33 (5.03) 1.41 (0.08)
Amphotericin-B (1.0 mg/L) 323.67(115.63) 2.49(0.16)
Table 8. Mean abundance of prezoosporangia in infected hemolymph samples after 
exposure to 100 mg/L treatments. Values indicate average of three replicate counts per 
0.2 mL pooled hemolymph sample. Standard deviation in parenthesis.
PREZOOSPORANGIA ABUNDANCE
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 387.00 (241.63) 2.53 (0.27)
Solvent control 902.33 (1012.18) 2.73 (0.56)
Amprolium 150.00 (166.96) 1.93(0.61)
Arprinocid 231.33 (155.03) 2.30 (0.27)
Cycloheximide 2.00(1.00) 0.46(0.15)
Lasalocid 1.67 (2.08) 0.33 (0.35)
Malachite green 1.67 (2.08) 0.33 (0.35)
Monensin 9.67 (1.53) 1.02 (0.06)
P. sulfadimethoxine 339.33 (147.55) 2.50(0.20)
Sulfadimethoxine 69.33 (37.90) 1.81 (0.22)
Figure 2. Mean abundance of prezoosporangia in infected hemolymph samples after 
exposure to 10 mg/L chemical treatments. Bars = means of 3 replicate 0.2 mL 
hemolymph samples. Error bars = standard errors. No error bars shown when replicate 
samples were equal. * = significantly lower (P < 0.05) than untreated control. 
Abbreviations: UC = untreated control, SC = solvent control, AMP = amprolium, CYC 
cycloheximide, LAS = lasalocid, MG = malachite green, MON = monensin, SUL = 
sulfadimethoxine.
UC SC AMP CYC LAS MG MON
TREATMENT
SUL
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Table 9. One way ANOVA and Dunnett tests describing the effects of 10 mg/L chemical 
treatments on mean prezoosporangia abundance in infected hemolymph samples.
Significance level = 0.05
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatment
Residual
6 14.732 
14 1.034
2.455
0.074
33.233 0.000
Dunnett’s test for mean < control
COMPARISON DIFFERENCE CRITICAL
DIFFERENCE
SIGNIFICANCE
Control vs. Malachite green -1.919 0.562 significant
Lasalocid -1.442 0.562 significant
Cycloheximide -0.446 0.562 not significant
Amprolium -0.381 0.562 not significant
Sulfadimethoxine 0.400 0.562 not significant
Monensin 0.468 0.562 not significant
40
Table 10. Mean abundance of prezoosporangia in infected hemolymph samples after 
exposure to 10 mg/L, 1 mg/L, 0.1 mg/L and 0.01 mg/L chemical treatments. Values 
indicate average of three replicate counts per 0.2 mL pooled sample. Standard deviation 
in parenthesis.
TREATMENT_______________________________ PREZOOSPORANGIA ABUNDANCE
10 me/L EXPOSURE UNTRANSFORMED TRANSFORMED
Untreated control 83.00 (15.59) 1.92 (0.09)
Solvent control 341.33 (47.71) 2.53 (0.06)
Amprolium 35.67 (15.82) 1.54(0.18)
Cycloheximide 50.00 (42.57) 1.47 (0.67)
Lasalocid 2.00 (0.00) 0.48 (0.00)
Malachite green 0.00 (0.00) 0.00 (0.00)
Monensin 248.00 (63.41) 2.39(0.11)
Sulfadimethoxine 210.00 (40.29) 2.32 (0.08)
1.0 me/L EXPOSURE
Amprolium 138.33 (81.38) 2.10(0.23)
Cycloheximide 100.33 (20.03) 2.00 (0.08)
Lasalocid 393.67 (51.60) 2.59 (0.06)
Malachite green 86.33 (28.94) 1.92 (0.16)
Monensin 297.33 (28.88) 2.47 (0.04)
Sulfadimethoxine 322.67 (48.76) 2.51 (0.06)
0.1 me/L EXPOSURE
Amprolium 130.00 (23.64) 2.11 (0.08)
Cycloheximide 127.67 (21.57) 2.10 (0.08)
Lasalocid 350.00 (209.01) 2.48 (0.31)
Malachite green 101.67 (32.19) 2.00(0.13)
Monensin 270.00 (76.22) 2.42 (0.14)
Sulfadimethoxine 349.00 (106.30) 2.53 (0.14)
0.01 me/L EXPOSURE
Amprolium 180.00(102.81) 2.21 (0.24)
Cycloheximide 126.67 (24.21) 2.10(0.09)
Lasalocid 269.33 (168.36) 2.34 (0.39)
Malachite green 172.33 (97.68) 2.19(0.26)
Monensin 399.00 (68.09) 2.60(0.07)
Sulfadimethoxine 359.33 (105.10) 2.54 (0.14)
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In tests with cultured P. marinus cells, there was a significant (P = 0.000) effect of 
treatment on prezoosporangia abundance (Fig. 3 and Table 11). Amphotericin-B and 
lasalocid treatments had significantly (P < 0.05) lower prezoosporangia abundance than 
the control treatment (Table 11). Average prezoosporangia abundance decreased from 
102 cells in the untreated control group to 35 cells in the amphotericin-B group, and from 
124 cells in the untreated control group to 2 cells in the lasalocid group (Table 12).
The effect of treatment on size of prezoosporangia was also significant (P =
0.000) (Fig. 4 and Table 13). Again, only cells exposed to amphotericin-B or lasalocid 
were significantly (P < 0.05) smaller in diameter than control cells. Mean diameter of 
prezoosporangia in the control groups ranged from 7.8 to 10.2 pm. Amphotericin-B 
treated cells averaged 6.7 pm, and lasalocid treated cells averaged 3.6 pm (Table 14).
There was also a significant (P = 0.000) effect of treatment on percent cell 
viability (Fig. 5 and Table 15). Among all compounds tested, only amphotericin-B, 
lasalocid, and monensin significandy (P < 0.05) reduced cell viability when compared to 
the control group. Mean viability of cells in control and amphotericin-B groups was 97% 
and 79% respectively (Table 16).
For all in vitro experiments, abundance and size of prezoosporangia were greater 
in solvent control groups than in untreated control groups. Cell viability was slighdy 
lower for solvent control groups than for untreated control groups.
Figure 3. Mean abundance of prezoosporangia per sample using cultured P. marinus 
cells after exposure to 100 mg/L chemical treatments. Abbreviations: UC = untreated 
control, SC = solvent control, AMB = amphotericin-B, CIM = cimetidine, CYC = 
cycloheximide, FLU = 5-flourocytosine, FUM = fumagillin, KET = ketoconazole. Bars 
means of 3 replicate counts. Error bars = standard errors. * = significantly lower (p < 
0.05) than untreated control.
UC SC AMB CIM CYC FLU FUM 
TREATMENT
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Table 11. One way ANOVA and Dunnett tests describing the effect of 100 mg/L
chemical treatments on prezoosporangia abundance in cultured P. marinus samples.
Significance level = 0.05.
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatm ent 6 58012.825 9668.804 6.817 0.000
Residual 56 79423.111 14818.270
Dunnett’s test for mean < control. Critical difference = 0.184.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Amphotericin-B -0.414 significant
Cimetidine -0.098 not significant
Ketoconazole -0.046 not significant
Fumagillin 0.097 not significant
Fluorocytosine 0.103 not significant
Cycloheximide 0.142 not significant
One way ANOVA and Dunnett tests describing the effect of 100 mg/L lasalocid and 
monensin treatments on prezoosporangia abundance in cultured P. marinus samples. 
Significance level = 0.05.
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatment 3 20.519 6.840 455.367 0.000
Residual 32 0.481 0.015
Dunnett* s test for mean < control. Critical difference = 0.122.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Lasalocid -1.607 significant
Monensin 0.169 not significant
Table 12. Mean abundance of prezoosporangia in cultured P. marinus samples after
exposure to 100 mg/L chemical treatments. Values indicate mean of three replicate
counts. Standard deviation in parenthesis.
PREZOOSPORANGIA ABUNDANCE
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 102.11 (46.70) 1.97 (0.21)
Solvent control 194.89 (341.44) 1.99 (0.46)
Amphotericin-B 35.67 (8.34) 1.55 (0.09)
Cimetidine 86.22 (53.77) 1.87 (0.25)
Cycloheximide 131.33 (30.52) 2.11 (0.10)
Fluorocytosine 124.78 (45.42) 2.07 (0.17)
Fumagillin 119.11(30.87) 2.07 (0.12)
Ketoconazole 86.56 (28.97) 1.92 (0.13)
Mean abundance of prezoosporangia in cultured P. marinus samples after exposure to 
100 mg/L lasalocid and monensin treatments. Values indicate mean of three replicate 
counts. Standard deviation in parenthesis.
PREZOOSPORANGIA ABUNDANCE
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 124.67 (26.18) 2.09 (0.08)
Solvent control 183.00 (28.22) 2.26 (0.06)
Lasalocid 2.33 (1.50) 0.48 (0.19)
Monensin 205.56 (46.63) 2.30(0.11)
Figure 4. Mean size of prezoosporangia in cultured P. marinus samples after exposure 
100 mg/L chemical treatments. Abbreviations: UC = untreated control, SC = solvent 
control, AMB = amphotericin-B, CIM = cimetidine, CYC = cycloheximide, FLU = 5- 
fluorocytosine, FUM = fumagillin, KET = ketoconazole. Bars = means of 75 
measurements. Error bars = standard errors. * = significantly lower (p < 0.05) than 
untreated control.
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Table 13. One way ANOVA and Dunnett tests describing the effects of 100 mg/L
chemical treatments on mean prezoosporangia size in cultured P. marinus samples.
Significance level = 0.05.
One^/a^anal^sm
SOURCE DF SS MS F-VALUE P-VALUE
Treatment 6 1.953 0.325 12.643 0.000
Residual 518 13.335 0.026
Dunnett’s test for mean < control. Critical difference = 0.060.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Amphotericin-B -0.107 significant
Ketoconazole -0.037 not significant
Fumagillin 0.011 not significant
Fluorocytosine 0.023 not significant
Cimetidine 0.056 not significant
Cycloheximide 0.098 not significant
One way ANOVA and Dunnett tests describing the effects of 100 mg/L lasalocid and 
monensin treatment on mean prezoosporangia size in cultured P. marinus samples. 
Significance level = 0.05.
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatment 3 2.145 0.715 45.545 0.000
Residual 251 3.941 0.016
Dunnett’s test for mean < control. Critical difference = 0.056.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Lasalocid -0.279 significant
Monensin -0.005 not significant
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Table 14. Mean size of prezoosporangia in cultured P. marinus samples after exposure to
100 mg/L treatments. Values indicate mean of 75 measurements Standard deviation in
parenthesis.
PREZOOSPORANGIA DIAMETER (urn)
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 9.20 (4.25) 0.96 (0.21)
Solvent control 10.20 (4.36) 1.01 (0.21)
Amphotericin-B 6.68 (2.86) 0.85 (0.16)
Cimetidine 10.08 (3.58) 1.02(0.16)
Cycloheximide 11.04(3.92) 1.06(0.13)
Fluorocytosine 9.20(3.32) 0.98 (0.14)
Fumagillin 8.84 (2.87) 0.97 (0.13)
Ketoconazole 8.04 (3.39) 0.93 (0.21)
Mean size of prezoosporangia in cultured P. marinus samples after exposure to 100 mg/L 
lasalocid and monensin treatments. Values indicate mean of 75 measurements. Standard 
deviation in parenthesis.
PREZOOSPORANGIA DIAMETER (urn)
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 7.88 (2.74) 0.93(0.12)
Solvent control 8.12 (2.35) 0.95(0.11)
Lasalocid 3.60(1.22) 0.65 (0.10)
Monensin 8.44(9.72) 0.92(0.15)
Figure 5. Mean percent cell viability in cultured P. marinus samples after exposure to 
100 mg/L treatments. Abbreviations: UC = untreated control, SC = solvent control, AMB 
= amphotericin-B, CIM = cimetidine, CYC = cycloheximide, FLU = 5-fluorocytosine, 
FUM = fumagillin, KET = ketoconazole. Bars = means of 2 replicate counts. Error bars = 
standard errors. * = significantly lower (p < 0.05) than untreated control.
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Table 15. One way ANOVA and Dunnett tests describing the effects of 100 mg/L
chemical treatments on percent cell viability in cultured P. marinus samples.
Significance level = 0.05.
One_wav^ial^sis_ofvariai^
SOURCE DF SS MS F-VALUE P-VALUE
Treatm ent 6 0.520 0.087 10.147 0.000
Residual 21 0.179 0.009
Dunnett’s test for mean < control. Critical difference = 0.160.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Amphotericin-B -0.325 significant
Fumagillin -0.087 not significant
Cimetidine 0.041 not significant
Fluorocytosine 0.045 not significant
Ketoconazole 0.070 not significant
Cycloheximide 0.107 not significant
One way ANOVA and Dunnett tests describing the effects of 100 mg/L lasalocid and 
monensin treatments on percent cell viability in cultured P. marinus samples. 
Significance level = 0.05.
One way analysis of variance
SOURCE DF SS MS F-VALUE P-VALUE
Treatment 2 6.580 3.290 1 .7 0 7 x l0 l9 0.000
Residual 9 1.735 x 10-18 1.927 x 10'19
Dunnett* s test for mean < control. Critical difference = 6.768 x 10' *0.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Lasalocid -1.571 significant
Monensin -1.571 significant
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Table 16. Mean percent viability in cultured P. marinus samples after exposure to 100
mg/L chemical treatments. Values indicate average of 2 replicates. Standard deviation in
parenthesis.
PERCENT VIABILITY
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 99.50 (1.00) 1.53 (0.07)
Solvent control 97.12(2.31) 1.42(0.10)
Amphotericin-B 79.20 (5.55) 1.10 (0.70)
Cimetidine 97.84 (2.54) 1.47 (0.12)
Cycloheximide 99.39 (1.22) 1.53 (0.78)
Fluorocytosine 97.98 (2.44) 1.47(0.12)
Fumagillin 94.63 (1.14) 1.34 (0.03)
Ketoconazole 98.77 (1.78) 1.49 (0.09)
Mean percent viability in cultured P. marinus samples after exposure to 100 mg/L 
lasalocid and monensin treatments. Values indicate average of 2 replicates. Standard 
deviation in parenthesis.
PERCENT VIABILITY
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated control 100 (0.00) 1.57 (0.00)
Solvent control 100.00 (0.00) 1.57 (0.00)
Lasalocid 0.00(0.00) 0.00 (0.00)
Monensin 0.00 (0.00) 0.00 (0.00)
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Toxicity experiment
Oysters from the baseline diagnostic sample were all negative for P. marinus. All 
solvent control oysters survived 96 hour exposure to 0.1% DMSO. Among the chemicals 
tested in this experiment, only lasalocid and monensin were lethal to oysters. The LC50 
for lasalocid was 0.51 mg/L as determined by the graphic method, and 0.59 mg/L with a 
95% confidence interval ranging from 0.1 to 10 mg/L by the binomial method (Table 
17A). Exposure to 1 mg/L and 10 mg/L of monensin for 96 hours resulted in 10 % and 40 
% mortality respectively (Table 17B).
In vivo experiments
At the start of experiment 1, more than half the oysters had light infections 
(prevalence = 56%, weighted prevalence = 0.76). By the end of the experiment, 
prevalence had increased to more than 80% for treatments and controls alike (Table 18). 
There was no significant effect of treatment on prevalence or weighted prevalence ?  = 
0.369, P = 0.632 respectively (Tables 18 and 19). Comparison of solvent challenged 
control groups and untreated challenged control groups did not reveal any effect of 
solvent on prevalence or weighted prevalence. However, prevalence and weighted 
prevalence were lower for challenged controls than for unchallenged controls (Tables 18 
and 19).
At the start of experiment 2, most oysters had light infections (<1000 P. marinus 
cells per 0.3 mL of hemolymph). Comparison of parasite cell abundance in hemolymph 
samples taken before and after treatment and among treated and untreated groups, 
revealed that only oysters exposed to cycloheximide had lower infections after treatment 
than they had before treatment (Fig. 6 and Table 20). Tissue samples showed an overall 
agreement with hemolymph samples, but intensity estimates were generally higher for 
tissue samples within each oyster. At the end of the 15 day period, weighted prevalence 
was significantly (P < 0.05) lower in oysters exposed to 10 mg/L of cycloheximide than
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in untreated controls. Average weighted prevalence was 2.10 and 3.78 respectively. In 
hemolymph samples, there was a significant (P = 0.015) effect of treatment on 
prezoosporangia abundance averaged over time. The effect of time alone, however, 
averaged over treatment, was not significant (P = 0.867). Nevertheless, the pattern of 
change over time was different for different treatments, as indicated by the significant 
(P = 0.000) effect of the interaction term (Table 21). In agreement with results from tissue 
diagnosis, only oysters exposed to 10 mg/L of cycloheximide had a significantly lower 
(P < 0.05) number of prezoosporangia per unit hemolymph than untreated controls.
No oysters survived exposure to 10 mg/L or 1 mg/L of malachite green after 15 
days. More than 50% (21 in 40) of the oysters exposed to malachite green were dead after 
chemicals were renewed four times. During the follow-up experiment, all oysters 
survived exposure to 0.1 mg/L and 0.01 mg/L of malachite green, but no effect on disease 
prevalence or infection intensity was detected at those concentrations.
In experiment 3, the first diagnostic sample indicated a 68% prevalence of mostly 
light infections (weighted prevalence = 0.92) at the time oysters were collected. Ten days 
after acclimation to 20°C and 20 ppt, prevalence had risen to 95% and intensities had 
increased (weighted prevalence = 1.85). Following 30 days of exposure to 
cycloheximide, infection prevalence and weighted prevalence declined to 67% and 0.71 
respectively (Figs. 7 and 8). At that time, oysters exposed to cycloheximide had fewer 
and lighter infections than untreated control oysters. The reduction in weighted 
prevalence between treated oysters and untreated control oysters after the treatment 
period, in this experiment, was similar to that in the previous experiment (i.e., a 1.50 
decline as compared to a 1.68 decline respectively). The effects of treatment on 
prevalence and weighted prevalence were both significant (P = 0.000 and P = 0.001 
respectively) (Tables 22 and 23). There was no significant (P = 0.235) effect of time on 
prevalence (prevalence was already at the maximum at 30 days in controls), but there was 
a significant ( P = 0.014) effect of time on weighted prevalence as it increased both in
control and treated oysters after treatment was halted (Fig. 8 and Table 23). The 
interaction effects of treatment and time on prevalence and weighted prevalence were not 
significant (P = 0.235 and P = 0.912 respectively).
There was no adverse effect of cycloheximide on oyster survival. Among 100 
oysters treated, only 8 died as compared to 4 that died among 100 untreated controls. 
Even though sublethal effects were not measured, no overall differences in soft tissue 
appearance or wet tissue weight between oysters exposed to cycloheximide and untreated 
controls were observed.
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Table 17A. Toxicity of lasalocid to oysters
Nominal concentration Mortality (%)
of exposure (mg/L)
24 hr. 48 hr. 72 hr. 96 hr.
0.00 0 0 0 0
0.01 0 0 0 0
0.10 0 0 0 0
1.00 50 70 70 70
10.00 70 90 100 100
Table 17B. Toxicity of monensin to oysters
Nominal concentration Mortality (%)
of exposure (mg/L)
24 hr. 48 hr. 72 hr. 96 hr.
0.00 0 0 0 0
0.01 0 0 0 0
0.10 0 0 0 0
1.00 0 0 10 10
10.00 0 0 30 40
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Table 18. In vivo experiment 1. Mean prevalence and one way ANOVA describing the
effect of chemical treatment on prevalence.
Prevalence after exposure of oysters to amprolium, arprinocid, lasalocid, monensin, 
potentiated sulfadimethoxine, and sulfadimethoxine. Values indicate means of two 
replicates. Standard deviations in parenthesis.
PREVALENCES)
TREATMENT UNTRANSFORMED TRANSFORMED
Untreated unchallenged 96 (0.00) 1.37 (0.00)
Untreated challenged 88 (5.66) 1.22(0.09)
Solvent challenged 94 (2.83) 1.33 (0.06)
Amprolium 96 (5.66) 1.43 (0.20)
Arprinocid 94 (2.83) 1.33 (0.06)
Lasalocid 100 (0.00) 1.57 (0.00)
Monensin 80(22.63) 1.15 (0.31)
Potentiated sulfadimethoxine 92 (0.00) 1.28 (0.00)
Sulfadimethoxine 94 (8.45) 1.39 (0.25)
One way ANOVA on transformed prevalence
SOURCE DF SS MS F-VALUE P-VALUE
Treatment 6 0.236 0.039 1.292 0.369
Residual 7 0.213 0.030
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Table 19. In vivo experiment 1. Mean weighted prevalence and one way ANOVA 
describing the effect of chemical treatment on weighted prevalence.
Weighted prevalence after exposure of oysters to amprolium, arprinocid, lasalocid, 
monensin, potentiated sulfadimethoxine, and sulfadimethoxine. Values indicate 
means of two replicates. Standard deviations in parenthesis.___________________
TREATMENT
WEIGHTED PREVALENCE
UNTRANSFORMED TRANSFORMED
Untreated unchallenged 2.80 (0.79) 0.57 (0.09)
Untreated challenged 1.84(0.17) 0.45 (0.03)
Solvent challenged 1.82 (0.24) 0.45 (0.02)
Amprolium 2.80 (0.62) 0.58 (0.07)
Arprinocid 2.22 (0.71) 0.50(0.10)
Lasalocid 2.94 (1.27) 0.58 (0.14)
Monensin 1.92 (0.91) 0.45 (0.14)
Potentiated sulfadimethoxine 1.76 (0.28) 0.44 (0.04)
Sulfadimethoxine 2.76 (1.19) 0.56(0.14)
One way ANOVA on transformed weighted prevalence
SOURCE________  DF SS MS F-VALUE P-VALUE
Treatment 6 0.048 0.008 0.745 0.632
Residual  7 0.075 0.011
Figure 6. In vivo experiment 2. Mean abundance of prezoosporangia in repeated 
hemolymph samples, before and after a 15 day exposure of infected oysters to chemical 
treatments. Abbreviations: UC = untreated control, AMP = amprolium, CYC = 
cycloheximide, SUL = sulfadimethoxine. Numbers following acronyms indicate 
concentration of exposure in mg/L. Note: One sample of the CYC1 group had more than
100,000 cells after treatment and was excluded from this chart Bars = means per 0.3 mL 
hemolymph samples averaged over 16-20 oysters. Dark bars indicate pre-treatment 
values. Light bars indicate post-treatment values. Error bars = standard errors. * = final 
value significantly lower (p < 0.05) than initial value, and overall value significantly 
lower (p < 0.05) than untreated control.
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Table 20. In vivo experiment 2. Mean abundance of piezoosporangia in repeated 
hemolymph samples before and after exposure of oysters to amprolium, cycloheximide, 
and sulfadimethoxine treatment. Values indicate means per 0.3 mL hemolymph samples 
averaged over 16-20 oysters. Standard deviation in parenthesis.
PREZOOSPORANGIA ABUNDANCE
TREATMENT
UNTRANSFORMED TRANSFORMED
INITIAL FINAL INITIAL FINAL
Untreated control 358 (893) 2913 (10630) 1.57 (1.00) 1.75 (1.34)
Amprolium 10 364 (580) 648(1173) 1.66 (1.05) 2.15 (1.04)
Amprolium 100 165(357) 3233 (9323) 1.32 (0.89) 2.38 (1.15)
Cycloheximide 1 788 (1835) 5769(24605) 1.88 (1.02) 1.05 (1.44)
Cycloheximide 10 233 (519) 25(111) 1.38 (0.98) 0.22 (0.61)
Sulfadimethoxine 10 272 (495) 4080 (10096) 1.52 (1.00) 1.78 (1.41)
Sulfadimethoxine 100 341 (811) 1440 (3627) 1.62 (0.89) 1.73 (1.25)
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Table 21. In vivo experiment 2. Repeated measures ANOVA, Dunnett and t-tests 
describing the effects of chemical treatments on prezoosporangia abundance in 
hemolymph samples. Significance level = 0.05.
RegeatedmeasureANOVA
SOURCE DF SS MS F-VALUE P-VALUE
TREATMENT 6 31.442 5.240 2.756 0.015
SUBJECT(GROUP) 123 233.901 1.902
TIME 1 0.015 0.015 0.028 0.867
TIME*TREATMENT 6 34.151 5.692 10.953 0.000
TIME*SUBJECT(GROUP) 123 63.918 0.520
Dunnett’s test for mean < control. Critical difference = 0.735.
COMPARISON DIFFERENCE SIGNIFICANCE
Control vs. Cycloheximide 10 -0.861 significant
Cycloheximide 1 -0.201 not significant
Sulfadimethoxine 10 -0.011 not significant
Sulfadimethoxine 100 0.011 not significant
Amprolium 100 0.185 not significant
Amprolium 10 0.240 not significant
Paired t-test for selected treatments. Hypothesized difference < or = 0.
TREATMENT MEAN DF t-VALUE P-VALUE
DIFFERENCE
Cycloheximide 10 1.167 19 5.045 0.000
Cycloheximide 1 0.777 19 2.944 0.004
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Figure 7. In vivo experiment 3. Prevalence after a 30 day exposure of oysters to 
cycloheximide, and prevalence 30 days after stopping exposure. UC = untreated control 
treatment, CYC10 = 10 mg/L cycloheximide treatment. The bar to the left of each group 
corresponds to the diagnostic sample (N = 25 oysters) taken immediately prior to the 
initiation of the experiment. Other bars indicate average of 2 replicate groups of 25 
oysters. Error bars = standard deviation. No error bars shown when replicate samples 
were equal.
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Figure 8. In vivo experiment 3. Weighted prevalence after a 30 day exposure of oysters 
to cycloheximide, and weighted prevalence 30 days after stopping exposure. 
Abbreviations: UC = untreated control treatment, CYC10 = 10 mg/L cycloheximide 
treatment. The bar to the left of each group corresponds to the diagnostic sample (N = 25 
oysters) taken immediately prior to the initiation of the experiment Other bars indicate 
average of 2 replicate groups of 25 oysters. Error bars indicate standard deviation. No 
error bars shown when replicate samples were equal.
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Table 22. In vivo experiment 3. Mean prevalence and two-way ANOVA describing the 
effects of cycloheximide treatment and time on prevalence.
Mean prevalence before and after exposure of oysters to cycloheximide. Values indicate 
mean of two replicates. Standard deviation in parenthesis.
TREATMENT PREVALENCE (%) TRANSFORMED PREVALENCE
time = 30 days time = 60 days time = 30 days time = 60 days
Untreated control 100.00 (0.00) 100.00 (0.00) 1.571 (0.00) 1.571 (0.00)
Cycloheximide 10 72.00 (8.29) 77.00 (2.83) 0.961 (0.11) 1.071 (0.03)
Two way ANOVA on transformed prevalence
SOURCE DF SS MS F-VALUE P-VALl
Treatment 1 0.616 0.616 198.694 0.000
Time 1 0.006 0.006 1.951 0.235
Treatment*Time 1 0.006 0.006 1.951 0.235
Residual 4 0.012 0.003
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Table 23. In vivo experiment 3. Weighted prevalence and two-way ANOVA describing 
the effects of cycloheximide treatment and time on weighted prevalence.
Mean weighted prevalence before and after exposure of oysters to cycloheximide. Values 
indicate mean of two replicates. Standard deviation in parenthesis.___________________
TREATMENT WEIGHTED PREVALENCE TRANSFORMED WEIGHTED 
PREVALENCE
time = 30 davs time = 60 days time = 30 days time = 60 days
Untreated control 2.21 (0.41) 3.42 (0.47) 0.51 (0.06) 0.64(0.05)
Cycloheximide 10 0.71 (0.17) 1.31 (0.20) 0.23 (0.04) 0.36 (0.04)
Two way ANOVA on transformed weighted prevalence
SOURCE____________DF________ SS__________ MS_________ F-VALUE P-VALUE
Treatment 1 0.153 0.153 71.583 0.001
Time 1 0.037 0.037 17.204 0.014
Treatment*Time 1 2.9 x 10*5 2.9 x 10'5 0.0141 0.912
Residual_____________4 0.009 0.002 ___________
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DISCUSSION
In vitro studies
Among the nine compounds tested on P. marinus-iniected hemolymph, six (i.e., 
amphotericin-B, cycloheximide, lasalocid, malachite green, monensin, and 
sulfadimethoxine) showed efficacy in inhibiting P. marinus cells from enlarging in FTM. 
Malachite green, amphotericin-B, and lasalocid, followed by cycloheximide, were the 
most effective compounds. The concentrations of malachite green active against P. 
marinus-infected hemolymph (100 mg/L to 10 mg/L) in the present study were higher 
than the range of 2 mg/L to 4 mg/L reported for effective concentrations against the 
model protozoan Tetrahymena pyriformis (Griffin 1989).
The results for cycloheximide were similar to those obtained by Ray (1966a). In 
Ray’s study, exposure of infected oyster tissue to 25 mg/L of cycloheximide for several 
weeks completely inhibited parasite enlargement In the present study, exposure of 
infected oyster hemolymph to 100 mg/L for 1 day significantly inhibited the number of P. 
marinus cells enlarging in FTM, and exposure to 10 mg/L resulted in some inhibition. 
Further comparison of results is not possible because Ray used pieces of infected tissues 
and described the degree of inhibition only as slight marked, or complete.
Among the eight compounds tested using cultured P. marinus cells, only two (i.e., 
amphotericin-B and lasalocid showed efficacy in inhibiting the number and size of cells 
enlarging to prezoosporangia stage. In addition to the above compounds, monensin 
reduced cell viability.
Four chemotherapeutants were tested both on P. marinus-infected hemolymph 
and cultured P. marinus cells. Three of them, amphotericin-B, lasalocid and monensin, 
had similar effects on parasites regardless of their source. Cycloheximide, however, was 
effective against parasites from infected hemolymph but not against cultured forms. The
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lack of detectable activity of cycloheximide on cultured parasites may be related to the 
presence of nutrients in the culture medium. It is possible that cultured cells eluded the 
adverse effects of cycloheximide on growth and viability by relying on amino acids 
present in the culture medium (La Peyie et al. 1993). Composition of culture media can 
alter not only susceptibility of parasites to chemotherapeutants but also their temperature 
tolerance, protein profile, and virulence (Cline et al. 1983, Marciano-Cabral & Toney 
1994). Alternatively, effects of cycloheximide on cultured cells may have occurred but 
were not detectable by the assay used. An assay based on amino acid incorporation into 
cultured cells would be more specific and sensitive for the determination of activity with 
cycloheximide than the one used in the present study based on enlargement or viability.
The concentrations of exposure of amphotericin-B active against P. marinus in 
the present study, 100 mg/L -10  mg/L, are in agreement with results by Ray (1966a). In 
Ray's study, P. marinus cells were markedly inhibited after exposure of infected tissues to 
50-100 mg/L of amphotericin-B. Exposure of infected tissues to less than 50 mg/L of 
amphotericin-B resulted only in slight inhibition. Concentrations in the range of 10 mg/L 
to 100 mg/L of amphotericin-B are, however, well beyond the recommended dose of 2.5 
mg/L for antifungal treatment of in vitro cultures (Sigma Chemical Co. 1993).
The concentrations of exposure of lasalocid and monensin active against P. 
marinus in the present study (100 mg/L to 10 mg/L) were much higher than the range 
0.001 mg/L to 0.005 mg/L found active against the coccidian Eimeria tenella by Ryley 
and Wilson (1976). A longer exposure duration (4 days in Ryley & Wilson's study as 
compared to 1 day in the present study) and possibly a more sensitive endpoint for 
activity (clusters indicating growth of specific life stages) may account for some of the 
difference.
The mechanism by which chemicals inhibit P. marinus is probably related to the 
general mode of chemical action. Amphotericin-B, cycloheximide, lasalocid, and 
monensin may be lethal to P. marinus cells. Amphotericin-B is a polyene antifungal
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antibiotic. The mode of action and toxicity of the polyenes have been attributed to their 
ability to bind to sterols in cell membranes producing alterations in permeability 
(Grayson, 1982). Polyether ionosphorus compounds (including lasalocid and monensin) 
are known to disrupt the electrochemical balance of ions, such as Na+ and K+, which are 
involved in maintaining the selective permeability of membranes thereby having a 
cytocidal effect. It is not known how coccidia are preferentially affected by polyether 
ionosphorus compounds, but it has been proposed that the lack of active transport 
mechanisms in coccidia may allow for selective activity of these compounds (McDougald 
1982). Cycloheximide is a protein synthesis inhibitor highly active against a large 
number of yeasts including fungal pathogens (Ennis & Lubin 1964), but a cytostatic 
effect is more likely to have occurred in short term exposures. The mode of action of 
cycloheximide is by inhibiting protein synthesis in eukaryotic ribosomes. The inhibition 
may involve blocking one or more steps in the initiation and elongation of peptide chains 
(Deacon 1984, Obrig et al. 1971).
To some extent, anticoccidial agents (particularly lasalocid and monensin) 
showed activity against P. marinus as expected based on the proposed affinities of this 
parasite to the coccidians. However, the fact that compounds that are usually considered 
antifungal agents (amphotericin-B, malachite green and cycloheximide) were also 
effective, does not support the conclusion that anticoccidial compounds are necessarily 
the most effective ones against P. marinus.
The implications of these results for the phylogenetic affiliation of P. marinus 
with fungi and apicomplexan organisms is difficult to assess because the spectrum of 
action of chemotherapeutants often ranges beyond a single group of organisms.
Polyether antibiotic anticoccidial compounds such as lasalocid and monensin, for 
instance, have shown activity against Gram-positive bacteria, mycobacteria, and fungi 
(Grayson 1982). Aryl-methane dyes, such as malachite green, have a broad spectrum of 
action against Gram-positive bacteria, fungi (especially oomycetes), and external
protozoan parasites of fish (Alderman 1985). Cycloheximide activity has been reported 
mainly in reference to fungi (Whiffen 1948, Grayson 1982), but it is active against 
eukaryotes in general (Deacon 1984). Polyene antibiotics such as amphotericin-B 
possess broad antifungal activity and some antiprotozoal activity. Activity of 
amphotericin-B, however, is mostly restricted to yeasts, fungi, and molds including 
Candida spp., Cryptococcus neoformans, Histoplasma capsulatum, and Blastomyces 
dermatidis (Merck & Co. 1986).
It should be noted that no adverse effects of DMSO were detected on P. marinus. 
To the contrary, it appears that DMSO may have prevented cell deterioration, as 
suggested by the higher prezoosporangia abundance in several solvent control groups as 
compared to untreated (FYRW) control groups. Control of microbial contamination by 
DMSO could account for the increased cell counts in solvent controls. This suggestion is 
supported by the indication that DMSO may not only act as a solvent without interfering 
with parasite development or host cell integrity, but by the fact that it may also serve to 
sterilize in vitro assays (Ryley & Wilson 1976).
Toxicity studies
Among the six anticoccidials tested in the toxicity experiment, only lasalocid and 
monensin caused oyster mortality when applied at 10 mg/L or 1 mg/L. Oyster mortality 
related to lasalocid and monensin exposure is not entirely surprising since both chemicals 
are polyether ionosphorus compounds known for toxic effects associated with their mode 
of action (McDougald 1982). It is difficult to compare acute toxicity of anticoccidials by 
bath administration in oysters with that by injection or oral administration in terrestrial 
organisms. In mice, the 24 h median lethal dose of lasalocid ranges from 64 mg/kg 
(intraperitoneal) to 146 mg/kg (oral) (Grayson 1982). In oysters, the 96 h LC50 for 
lasalocid by bath administration was 0.56 mg/L (this study). Assuming one 24 h 
exposure of 1 mg/L of lasalocid to 10 oysters weighing an arbitrary average wet weight
protozoan parasites of fish (Alderman 1985). Cycloheximide activity has been reported 
mainly in reference to fungi (Whiffen 1948, Grayson 1982), but it is active against 
eukaryotes in general (Deacon 1984). Polyene antibiotics such as amphotericin-B 
possess broad antifungal activity and some antiprotozoal activity. Activity of 
amphotericin-B, however, is mostly restricted to yeasts, fungi, and molds including 
Candida spp.. Cryptococcus neoformans, Histoplasma capsulatum, and Blastomyces 
dermatidis (Merck & Co. 1986).
It should be noted that no adverse effects of DMSO were detected on P. marinus. 
To the contrary, it appears that DMSO may have prevented cell deterioration, as 
suggested by the higher prezoosporangia abundance in several solvent control groups as 
compared to untreated (FYRW) control groups. Control of microbial contamination by 
DMSO could account for the increased cell counts in solvent controls. This suggestion is 
supported by the indication that DMSO may not only act as a solvent without interfering 
with parasite development or host cell integrity, but by the fact that it may also serve to 
sterilize in vitro assays (Ryley & Wilson 1976).
Toxicity studies
Among the six anticoccidials tested in the toxicity experiment, only lasalocid and 
monensin caused oyster mortality when applied at 10 mg/L or 1 mg/L. Oyster mortality 
related to lasalocid and monensin exposure is not entirely surprising since both chemicals 
are polyether ionosphorus compounds known for toxic effects associated with their mode 
of action (McDougald 1982). It is difficult to compare acute toxicity of anticoccidials by 
bath administration in oysters with that by injection or oral administration in terrestrial 
organisms. In mice, the 24 h median lethal dose of lasalocid ranges from 64 mg/kg 
(intraperitoneal) to 146 mg/kg (oral) (Grayson 1982). In oysters, the 96 h LC50 for 
lasalocid by bath administration was 0.56 mg/L (this study). Assuming one 24 h 
exposure of 1 mg/L of lasalocid to 10 oysters weighing an arbitrary average wet weight
of 5 g per oyster, in a 10 L bath, and assuming that all the available compound was taken 
up in equal parts by oysters and no losses occurred, would result in a tissue concentration 
of 1 mg of the compound per 5 g wet tissue weight, or a dose equivalent to 200 mg/kg 
which is comparable to the acute toxic dose of lasalocid by oral administration for mice 
as previously noted. Most likely, however, only some fraction of the compounds was 
taken up by oysters and even less was available to the parasites. To better compare acute 
toxicity of compounds to aquatic organisms with that of terrestrial organisms, perhaps the 
preferred mode of administration of compounds would be by injection. It should also be 
noted that there was no oyster mortality associated with exposure to 0.1% DMSO, 
suggesting that DMSO can be used as a solvent at that or lower concentrations.
In addition to anticoccidials affecting oyster survival in the toxicity experiment, 
malachite green was lethal to oysters in experiment 1 (in vivo). Similar to monensin and 
lasalocid, 10 mg/L and 1 mg/L exposures of malachite green resulted in oyster mortality 
while 0.1 mg/L and 0.01 mg/L did not. Even though experiment 1 was not designed to 
determine median lethal doses, results suggest that acute toxicity of malachite green to 
oysters may be in the range of that for most freshwater invertebrates (0.51 mg/L - 3.45 
mg/L) but lower than that for the Asiatic clam Corbicula leana (122 mg/L), as reported 
by Bills et al. (1977). Malachite green is a respiratory enzyme poison known to destroy 
mitochondria (Alderman 1985). In addition to its destructive action against 
mitochondria, malachite green is known to be teratogenic in laboratory animals, and its 
use in aquaculture in the US has therefore not been approved by the FDA (Meyer & 
Schnick 1989).
In vivo studies
Experiment 1, designed to determine the effect of chemical baths on preventing 
infections, had some drawbacks and its results should be interpreted with caution.
Despite the fact that oysters were collected from an area that had traditionally been free
from P. marinus, the Wye River in Maryland, the baseline diagnostic sample showed 
56% prevalence of mostly light infections. Therefore, treatment was not strictly 
preventive in the sense that some infections were already established prior to exposure of 
oysters to chemical baths. This experiment was not repeated because, at the time, no 
source of P. marinus- free oysters was known.
Anticoccidial compounds, including lasalocid and monensin that were active in 
vitro at concentrations ranging from 10 mg/L to 1 mg/L, were not effective in vivo at 0.1 
mg/L. It is possible that exposure of oysters to 0.1 mg/L of lasalocid and monensin for 4 
days was not sufficient to deliver therapeutic levels of these compounds to parasites. 
Exposure of oysters to lasalocid or monensin at concentrations above 1 mg/L, however, 
was lethal to oysters, as indicated in the toxicity experiment. Therefore, for lasalocid and 
monensin the difference between a therapeutic dose and a toxic dose in oysters may be, if 
existent, between 0.1 and 1 mg/L. Small differences between therapeutic and toxic doses 
of lasalocid and monensin were typical in poultry and other animals (McDougald 1982 
and 1990).
Oysters (N = 25) challenged with one daily dose of lx 10? P. marinus cells from 
minced oyster tissues for two consecutive days did not exhibit increase infections relative 
to unchallenged control oysters. Therefore this challenge was not effective. Mantle 
cavity injections containing > 5 x 10^ P. marinus cells per oyster resulted in disease- 
induced mortality after 3 weeks (Mackin 1962). Considering that the "injection method" 
is more effective in producing P. marinus infections than the "feeding method" (Ray 
1954), the dose and duration of the challenge in experiment 1 may have been below that 
required to detect an increase in the number infections. Prior studies using the "feeding 
method" with P. marinus-infected tissue minces (Ray 1954, Mackin 1962) have not 
reported infective doses in terms of cells but in terms of number of infected oysters used 
as a source of parasites, usually ranging from 1 -10.
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In poultry, preventive anticoccidial treatment has been preferable to therapeutic 
treatment because coccidiosis is not clinically recognizable until tissue damage associated 
with second or third generation schizonts and mortality occurs soon after those signs 
appear. Initiation of treatment as soon as clinical signs appear is of value because not all 
individuals in a group become infected at the same time (McDougald 1982). Similarly, 
preventive or early treatment of P. marinus infections may be more effective than 
therapeutic treatment of advanced infections.
Among all compounds tested in experiment 2, designed to examine the effect of 
chemical baths on established infections, only cycloheximide was effective in controlling 
P. marinus infections while not adversely affecting oyster survival. In contrast to what 
has been reported for low salinity exposures (Ragone & Burreson 1993), infections did 
not merely stop progressing, but regressed significantly after exposure to cycloheximide. 
Both hemolymph and tissue samples confirmed reduction of infections, indicating that 
the chemical exposure had some parasiticidal effect. Short term medication may arrest 
parasite development whereas long term medication may kill the parasite. This 
conclusion agrees with results reported for other antiparasitic compounds (McDougald 
1982).
Tissue samples generally showed higher infection intensities than hemolymph 
samples suggesting perhaps that established infections in the tissues were not as easily 
affected by the chemical as parasites circulating in the hemolymph. Alternatively, higher 
parasite abundance in the tissues as compared to hemolymph may only be indicative of a 
difference in sensitivity of the two assays; the tissue diagnostic assay being more 
sensitive than the hemolymph assay, as proposed by Burreson and Ragone-Calvo (1993). 
On the basis of the in vitro efficacy of amphotericin-B, both on hemolymph and cultured 
cells, in vivo trials may be conducted in the future. No attempts to test amphotericin-B in 
vivo were carried out during the present investigation because the compound was tested
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during the last part of the study. In addition, amphotericin-B is a relatively expensive 
compound.
Experiment 3 clearly defined the effect of cycloheximide on prevalence and 
weighted prevalence. Prevalence declined from 95% (prior to treatment) to 67% (after 
30 days of exposure to cycloheximide) and weighted prevalence declined from 0.92 to 
0.71. These results are in general agreement with those reported by Ray (1966b). In 
Ray's study, however, prevalence only slightly declined from 95% (prior to treatment) to 
80% (after 30 days of exposure to cycloheximide) while weighted prevalence was 
drastically reduced from 3.00 to 1.25. Greater sample size in experiment 3 (N = 25) as 
compared to Ray's study (N = 10) may provide more confidence to differences detected 
in experiment 3. The magnitude of decline in weighted prevalence after treatment was 
similar to experiment 2, suggesting that 15 more days of treatment were not enough to 
further reduce infections. However, the fact that several light infections in treated oysters 
comprised only a few cells may have prevented a greater effect from being detected. 
Thirty days after stopping treatment, prevalence rose to 77% and weighted prevalence 
increased to 1.31 in the treated group. A similar increase in weighted prevalence 
occurred in the untreated control group. The mode of action of cycloheximide, as an 
inhibitor of protein synthesis, probably accounts for the temporary regression of 
infections during treatment and subsequent recurrence of infections once treatment was 
removed. Cells that survive treatment may be metabolically inactive during the treatment 
period. Perhaps a better strategy to control P. marinus infections with cycloheximide 
would be to treat infected oysters for 1-2 weeks to kill metabolically active parasites, 
withdraw treatment for 1 week to allow "dormant" parasites to develop, followed by 
another cycloheximide treatment. This schedule could be repeated until infections were 
eliminated or greatly reduced.
In agreement with Ray (1966b), experiment 3 showed that exposure of infected 
oysters to 10 mg/L of cycloheximide for 30 days resulted in a decrease in infection
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prevalence and intensity. In experiment 3, prevalence declined from 100% (in the 
untreated control group) to 67% (in the treated group) and weighted prevalence declined 
from 2.21 to 0.71 respectively.
The magnitude of decline in weighted prevalence in experiment 2 was also similar 
to the one observed in experiment 3, suggesting that 15 mote days of treatment were not 
enough to further reduce infections. However, the fact that several light infections of 
treated oysters comprised only a few cells in experiment 3 may have prevented a greater 
effect from being detected. The increase in prevalence and weighted prevalence after 
treatment stopped in experiment 3 suggests that the parasiticidal effect of cycloheximide 
did not persist beyond the exposure period.
In vitro assays have proven to be useful to screen anti-P. marinus compounds, but 
in vivo tests are necessary to identify suitable compounds for treatment of oyster diseases. 
Not only does a compound need to be active against the parasite but it also needs to be 
available to established infections and not harmful to the host. This agrees with 
conclusions for testing of antiparasitic compounds in other animals (Lichtfield 1958, 
Schnitzer & Hawking 1963, Ryley & Wilson 1976, Grayson 1982). Comparison of in 
vitro activity with in vivo efficacy in the present study indicates that even though several 
compounds were active in vitro, only cycloheximide was efficacious in vivo. Lasalocid 
and monensin, which were also active in vitro, were toxic to oysters in vivo. Difficulties 
in correlating in vitro activity with in vivo efficacy are not unusual and limit the utility of 
in vitro tests for predicting in vivo efficacy. Compounds that are very active in vitro may 
not be active in vivo, and compounds with minimal in vitro activity may be efficacious in 
vivo (Ryley & Wilson 1976).
Sources of discrepancies between in vitro and in vivo tests may be attributed in 
part to pharmacodymamics and bioavailability of test compounds to parasites in their host 
environment. In the present investigation, delivery of compounds via water baths must 
have provided enough quantity of lasalocid and monensin to oysters on the basis of the
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recorded toxic effects. Similarly, enough cycloheximide must have reached established 
parasites in oysters given the observed decrease of infections after treatment. It was 
assumed that delivery of chemicals mixed with algae or delivered at the same time algae 
were provided to aquaria would facilitate uptake by oysters. No measurements were 
taken, however, to validate this assumption. Availability of chemicals to oysters may in 
fact have been altered by factors such as uptake by algae and loss of chemicals to the air 
interface.
In solution, polyether antibiotic agents such as lasalocid and monensin assume a 
specific configuration with the center negatively charged and the exterior neutral and 
hydrophobic (McDougald 1982). The exterior hydrophobicity of polyether compounds 
may facilitate their interaction with organic matter including algae. If so, mixing 
polyether compounds with algae may be a good way to administer these compounds to 
oysters. With micro-encapsulation techniques (Langdon & Bolton 1984) it may be 
possible to improve the delivery of lasalocid and monensin to parasites while avoiding 
probable toxic effects to oysters. A recently developed liposomal amphotericin-B 
formulation has shown superior efficacy in the treatment of leishmaniasis and no toxicity 
to humans. A similar approach may be appropriate for use on oysters, even though the 
referred liposomal amphotericin-B formulation is too expensive even for use in humans 
(Olliaro & Bryceson 1993).
Cycloheximide is known to be toxic to algae (Bower 1989), but whether uptake 
by algae would alter the availability of cycloheximide to oysters is open for speculation. 
In aquatic organisms, uptake of chemicals may occur directly from the water through 
absorptive epithelia or from the food via the digestive tract. Uptake of compounds 
adsorbed to food or sediment particles has generally been considered negligible compared 
to uptake from water, but studies including those for bivalves have been contradictory 
(Langston 1978, Pruell et al. 1986, and Williams 1989)
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Loss of chemicals to the air interface may have occurred in the present study 
considering that a continuous supply of air bubbles was being delivered to aquaria by air 
stones. Use of Plexiglas covers, such as the ones used in the present study, can prevent 
chemicals form escaping from aquaria into the surrounding space to some extent, but 
offer no assurance against losses of chemicals to the air.
Very little is known about the effects of seawater on the activity of anticoccidial 
and antifungal compounds because the compounds have usually been used on terrestrial 
or freshwater organisms. Malachite green in alkaline waters rapidly transforms to the 
carbinol form which has greater liposolubility and may be more easily absorbed by skin 
and gills of fish (Alderman 1985). Cycloheximide may lose its activity in seawater (Ray 
1966). Therefore, direct measurements of the chemicals in the water and in oyster 
tissues would be necessary to determine the availability of the chemicals to oysters and 
parasites.
The recently developed P. marinus cell cultures (La Peyre et al. 1993) facilitates 
screening of compounds in vitro, but the advantage of using propagated cells may be 
offset if, as in the case of cycloheximide, no activity can be detected. Further studies are 
needed to compare and refine tests using culture and non-cultured P. marinus cells. 
Studies that may follow this line of research, however, should also note that the potential 
applications of chemotherapy to P. marinus-infected oysters may be restricted to small 
lots of oysters maintained in closed systems. It is debatable whether this approach would 
be practical for aquaculture situations where oysters must be grown “in the field.” In 
nature, disease pressure from P. marinus is probably continuous during the warm months 
and oysters would be re-exposed to infections after treatment. Furthermore, additional 
studies concerning the persistence of the chemical in the oyster and in the environment 
would be necessary to comply with regulatory requirements.
In summary, cycloheximide baths of at least 10 mg/L renewed every other day for 
2 weeks are necessary to reduce P. marinus infections in oysters held at 20 °C and 20 ppL
Continuation of treatment for 2 additional weeks may not result in eradication of the 
parasites. Infections may relapse once treatment is stopped and mortalities will most 
likely follow. Given its potential to cause harmful effects in humans, the use of 
cycloheximide is currently restricted to laboratory applications. All other uses have been 
canceled by EPA (Carl Grable, Environmental Protection Agency, pers. comm.).
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Appendix A. Structure of chemotherapeutants used in the present investigation. Note: 
Potentiated sulfadimethoxine, a compound based on sulfadimethoxine is not shown.
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Appendix B. List of compounds tested in vitro on oyster hemolymph infected with P. 
marinus and on cultured P. marinus cells. * = Compounds tested both on infected 
hemolymph and cultured cells.
Compounds tested on infected hemolymph________ Compounds tested on cultured cells
♦Amphotericin-B *Amphotericin-B
Amprolium Cimetidine
Arprinocid Cycloheximide
*Lasalocid Fumagillin
Malachite green 5-Fluorocytosine
*Monensin Ketoconazole
Potentiated sulfadimethoxine *Lasalocid
Sulfadimethoxine ♦Monensin
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